Latest studies
Every paper our editors flag with a plain-language note and an evidence rating. Filter by evidence, species, or design to find what actually applies to you.
- Study · TirzepatideWeak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
This US cost-effectiveness simulation compared tirzepatide against semaglutide (both at maximum tolerated dose) for obesity or overweight, using head-to-head SURMOUNT-5 trial data as its clinical engine. Researchers reported the model estimated tirzepatide to be both less costly (about $41,688 saved per patient, societal perspective) and more effective on modelled outcomes (0.506 QALYs gained), projecting fewer future cases of type 2 diabetes and cardiovascular disease. This is an economic model, not new clinical evidence: outputs depend on SURMOUNT-5's weight-loss advantage for tirzepatide plus many pricing and progression assumptions, and the sensitivity analyses matter for interpretation. It usefully frames a real decision, the two leading agents head to head, but the QALY and cost figures are projections, not observed outcomes, and the disclosed sponsorship context of such models warrants a careful read.
Journal of medical economicsn=——Dec 1, 2026 - Study · TirzepatideMixed
Sleeve gastrectomy versus tirzepatide to improve survival among patients with stage 5 CKD: A Markov decision analysis.
A decision-analytic model, not observed patient outcomes — projections inherit every input assumption, including the durability of drug-induced weight loss and perioperative mortality estimates in a high-risk CKD population. The core message, that magnitude and durability of weight loss drive survival in stage 5 CKD, is defensible; the specific life-year figures are not measurements. Relevant to transplant-eligibility weight thresholds, where this surgery-versus-incretin tradeoff is a live question.
American journal of surgeryn=——Nov 1, 2026 - Study · RetatrutideMixed
Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
This is an analytical chemistry paper, not a clinical study, so it says nothing about efficacy or safety. Its practical significance is quality verification: a validated, high-accuracy method covering approved and pipeline GLP-1 agonists in one run is directly useful for authenticating products in a market where counterfeit and compounded GLP-1 formulations are a live concern. The validation metrics reported are solid for the class, though independent replication in other labs is the usual next step. Relevant to readers who follow product-testing and vendor-credibility questions rather than clinical outcomes.
Journal of chromatography. An=——Oct 11, 2026 - Study · TirzepatideMixed
Differential Biliary Adverse Event Signals Among Glp-1 Receptor Agonists: A FAERS Disproportionality Analysis.
FAERS disproportionality analyses can rank reporting patterns, not measure true incidence — reporting is voluntary and confounded by publicity, prescribing volume, and indication. Several of the between-agent differences here are small, with PRRs near 1.0, and rarer outcomes lost significance in sensitivity analyses. The consistent class-wide biliary signal is the durable takeaway, in line with known trial data on gallstone risk; the agent-to-agent rankings should be held loosely.
Digestive diseases and sciencesn=——Oct 1, 2026 - Study · TirzepatideMixed
A Systematic Review and Meta-Analysis of Malnutrition and Metabolic Failure in High-Potency Incretin Therapy.
The gap between investigator-reported malnutrition (0.12%) and objective laboratory flags (2.9% vs 1.77% on placebo) is the notable finding, suggesting standard adverse-event reporting understates nutritional risk on high-potency incretins. Trial populations and endpoints vary across the SURMOUNT, STEP, SCALE, and OASIS programs, so pooled deficits are estimates, and the proposed monitoring algorithm is the authors' construct, not a tested protocol. Most relevant to older adults and anyone sustaining large deficits without attention to protein intake and resistance training.
Obesity science & practicen=—HumanOct 1, 2026 - Study · TirzepatideWeak / none
Tirzepatide for treatment of postbariatric hypoglycemia after Roux-en-Y gastric bypass: a report of 3 cases.
A three-patient case series, so this sits low on the evidence ladder, but postbariatric hypoglycemia has few good options and the use of continuous glucose metrics (time in range, variability) gives the observations some objectivity. It is also mechanistically counterintuitive — incretin agonism might be expected to worsen post-meal insulin surges, not blunt them — which makes the finding worth flagging. Controlled studies and dosing work are needed, as the authors acknowledge.
JCEM case reportsn=—HumanOct 1, 2026 - Study · TirzepatideSupported
What obgyns need to know about GLP-1 receptor agonists.
A single-author narrative review, but one addressing questions with real practical stakes for reproductive-aged women, who make up a large share of GLP-1 users. The contraception interaction with tirzepatide and the preconception-discontinuation guidance are drawn from manufacturer labeling and emerging cohort data rather than dedicated trials. The call for pregnancy registries is well placed — the human exposure data remain thin.
Current opinion in obstetrics & gynecologyn=——Oct 1, 2026 - Study · SemaglutideMixed
Implications of Glucagon-Like Peptide-1 Receptor Agonists in Otolaryngology - Head and Neck Surgery: A Review.
A specialty-focused narrative review that usefully collects effects scattered across the head and neck literature, both favorable and concerning. The evidence quality behind each claim varies widely — the sleep apnea benefit rests on randomized trial data, while the sinusitis, olfaction, and hearing threads are early and speculative. The balanced handling of the thyroid cancer question, where animal signals have not been confirmed in population studies, is appropriately cautious.
The Annals of otology, rhinology, and laryngologyn=——Oct 1, 2026 - Study · TirzepatideSupported
Comparative Efficacy of Tirzepatide Versus Semaglutide for Weight Loss in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis of Head-to-Head Studies.
The pooled sample is large and the effect direction is consistent across subgroups by study design and diabetes status, but only some of the ten included studies are randomised - observational comparisons of these two drugs are vulnerable to who gets prescribed what. The serious-adverse-event finding (RR 1.83) deserves attention precisely because it runs against the otherwise similar tolerability profile, and it comes from event counts that meta-analyses handle less reliably than continuous outcomes. Readers should regard the 4-point weight difference as an average, not a prediction for any individual.
Clinical obesityn=—HumanOct 1, 2026 - Study · TirzepatideSupported
Early changes in body composition with tirzepatide in adults with obesity: a real-world BIA study.
Muscle preservation is the question our readers ask most about the incretin drugs, and this small Greek clinic cohort offers an early real-world answer: roughly four-fifths of weight lost was fat, and the relative share of lean mass actually rose. The caveats matter — 51 people, 12 weeks, no control group, and bioelectrical impedance is a rougher instrument than DEXA. Still, the fat-to-lean ratio here is consistent with what the SURMOUNT trial substudies reported, which lends the finding credibility.
Nutrition (Burbank, Los Angeles County, Calif.)n=—HumanOct 1, 2026 - Study · TirzepatideWeak / none
Tirzepatide attenuates lipopolysaccharide-induced acute lung injury via AMPK/NF-κB signaling pathway.
A mechanistic mouse study in which tirzepatide is the direct subject, exploring anti-inflammatory effects in lipopolysaccharide-induced lung injury via the AMPK/NF-κB pathway. The signal that inflammatory and injury markers were reduced is coherent and supported by inhibitor experiments, but this is early preclinical work well outside tirzepatide's metabolic indications. It should be read as hypothesis-generating and not extrapolated to people.
Tissue & celln=—AnimalOct 1, 2026 - Study · TirzepatideWeak / none
Glucagon-like receptor-1 agonists and impotence: A meta-analysis.
Two hundred thirty-seven men across seven heterogeneous studies is a thin base for pooled hormone estimates, and the confidence interval on total testosterone (MD 73.04, CI 16.91 to 129.17) is wide enough to span clinically trivial and clinically meaningful. The analysis is class-level, so semaglutide and tirzepatide appear as search terms rather than as separately estimated arms — nothing here supports an agent-specific effect. Weight loss itself raises testosterone in men with obesity, and the design cannot separate that from any direct drug effect. Directionally reassuring against the post-marketing impotence reports, but no more than that.
World journal of methodologyn=—HumanSep 20, 2026 - Study · RetatrutideSupported
Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice.
A genuinely useful comparative design — same models, same readouts, three agents — and the pathway dissection (PI3K-AKT for semaglutide, PI3K-AKT plus PPAR for tirzepatide, PI3K-AKT plus NF-kB for retatrutide) gives mechanism rather than just an endpoint. The limits are the usual ones: mouse ureteral-obstruction and ageing models are aggressive surrogates for human chronic kidney disease, and a single dose level per agent cannot establish that retatrutide is more potent in people. The authors frame it as hypothesis-generating, which is the right register. Retatrutide remains investigational and unapproved.
iSciencen=—AnimalSep 18, 2026 - Study · RetatrutideSupported
CARDIOVASCULAR EFFECTS OF INCRETIN RECEPTOR AGONISTS: BEYOND GLYCEMIC CONTROL.
A narrative review, but one that assembles genuinely current material: SUMMIT cardiac-MRI data showing reverse ventricular remodelling with tirzepatide, and isolated human atrial tissue work showing direct inotropic effects of retatrutide. The retatrutide cardiovascular story remains surrogate-only until TRIUMPH outcome data report, which the authors acknowledge. A useful synthesis of the mechanism-beyond-glycemia argument.
Canadian journal of physiology and pharmacologyn=——Sep 10, 2026 - Study · TirzepatideWeak / none
Tirzepatide and oral progestogens: A hypothesis-generating review of a biologically plausible pharmacokinetic interaction in gynaecologic disease control and menopausal hormone therapy.
Explicitly hypothesis-generating: one pharmacokinetic study in a different formulation is the entire human evidence base, and the authors are careful to note that a lower peak concentration does not equal lost efficacy. Still, the question is practical for a large and growing patient overlap, and the initiation-and-dose-escalation window framing is actionable. A sensible flag, not a demonstrated interaction.
Maturitasn=——Sep 10, 2026 - Study · TirzepatideMixed
Increased Energy Expenditure through Intermittent Cold Exposure Does Not Enhance Tirzepatide Induced Weight-loss in Obese Mice.
A clean null result on a reasonable hypothesis: boosting energy expenditure through cold-induced thermogenesis did not stack with tirzepatide's intake suppression. The design has strengths — both sexes, controlled diet-induced obesity — but a single mouse dose and a three-week window limit inference, and rodent cold-exposure protocols map poorly onto human behavior. Useful for tempering the 'stack cold plunges with GLP-1s' extrapolations circulating in the community.
American journal of physiology. Regulatory, integrative and comparative physiologyn=—AnimalSep 10, 2026 - Study · TirzepatideSupported
Comparative outcomes for tirzepatide versus glucagon-like peptide-1 receptor agonists in patients with inflammatory bowel disease: a national propensity matched study.
Propensity-matched with 3,042 patients per arm — sizable for an IBD pharmacoepidemiology question — but retrospective, so residual confounding, including differential weight loss and adherence, can't be excluded. The effect is modest (aHR 0.81 for IV steroids) and drives the composite endpoint largely on its own. The authors appropriately call for prospective validation before drawing mechanistic conclusions.
Intestinal researchn=—HumanSep 10, 2026 - Study · TirzepatideMixed
Tirzepatide and the Incidence of Atrial Fibrillation in Adults With Overweight or Obesity: An Updated Meta-Analysis of Randomized Controlled Trials.
Bayesian rare-event methods are the right tool here, and the credible intervals tell the story: the atrial-fibrillation estimate (OR 2.20, 95% CrI 0.81-6.75) is compatible with anything from no effect to a large one. The any-arrhythmia signal just crosses significance and warrants monitoring rather than alarm. Event counts this low mean longer trials and pharmacovigilance data will settle the question, not this analysis — a point the authors themselves make.
Journal of the American Heart Associationn=—HumanSep 9, 2026 - Study · TirzepatideSupported
Semaglutide and Tirzepatide for the treatment of MASH: What Works, What's Coming, and What's Missing.
A narrative review, so it synthesizes rather than adds evidence, but its anchors are solid: interim phase 3 data behind semaglutide's accelerated MASH approval and consistent phase 2 fibrosis signals for tirzepatide. The open questions it flags — durability, long-term liver outcomes, safety over years — are the right ones. Senior author Tacke is a leading name in hepatology, which lends weight to the framing.
Digestionn=——Sep 9, 2026 - Study · TirzepatideWeak / none
Anesthetic Safety and Perioperative Outcomes in GLP-1 Receptor Agonist-Treated Patients Undergoing Lipoabdominoplasty.
A reassuring data point on the perioperative question that has dominated anesthesiology guidance since 2023, but a limited one: retrospective, single-protocol, and the authors themselves stress it was not powered for equivalence or for rare events such as aspiration. Absence of a detected signal in 98 exposed patients is not proof of safety. Useful context for patients planning body-contouring surgery after GLP-1 weight loss, not a basis to relax pre-operative precautions.
Aesthetic plastic surgeryn=—HumanSep 9, 2026 - Study · TirzepatideMixed
Current and forthcoming pharmacotherapies for adolescent obesity: Evidence-based review.
A minireview with a stated but not fully systematic search, so the 16.1 percent BMI figure should be read as drawn from the adolescent semaglutide trial programme rather than independently pooled here. The honest part is the gap it names: adolescent evidence for tirzepatide and for the cagrilintide-semaglutide combination is close to absent, and long-term safety data in a growing population do not yet exist. The equity and cost discussion is the practical constraint clinicians will recognise. Adolescent dosing is a prescriber decision, not a reported-protocol question.
World journal of clinical pediatricsn=——Sep 9, 2026 - Study · TirzepatideSupported
Association of tirzepatide with reverse cardiac remodeling and improved diastolic function in obesity-related HFpEF: A prospective real-world cohort study.
A single-center, single-arm observational cohort of 50 — no control group, so regression to the mean and concurrent care changes cannot be excluded, and echocardiographic endpoints in unblinded settings carry measurement bias. That said, the direction and magnitude align with the randomized SUMMIT program, and the multiplicity control is more rigorous than typical for real-world series. Best read as corroborating evidence, not an independent demonstration.
International journal of cardiologyn=—HumanSep 8, 2026 - Study · TirzepatideWeak / none
Metformin-Associated Lactic Acidosis and Relative Euglycemic Ketoacidosis Precipitated by a Glucagon-Like Peptide-1 Receptor Agonist: A Case Report and Literature Review.
A single case plus a small literature review, but the safety lesson is concrete: the nausea, vomiting, and reduced intake common on incretin drugs can set up dehydration and kidney injury that lets metformin accumulate, while a deceptively normal glucose masks the ketoacidosis. This is a rare combination — MALA itself occurs in fewer than 10 per 100,000 patient-years — so the finding warrants awareness, not alarm. The clinical takeaway is early ketone measurement in sick patients on this drug combination.
Kidney360n=—HumanSep 4, 2026 - Study · TirzepatideWeak / none
Case report: Tirzepatide-responsive refractory diabetes mellitus in an adult female with prader-willi syndrome.
A single case, so no generalizable conclusions — but Prader-Willi syndrome is a population where appetite-driven obesity is uniquely severe and therapeutic options are thin, which gives the observation some weight. The within-patient comparison (tirzepatide succeeding where a GLP-1 mono-agonist fell short) is suggestive of the added GIP component mattering, though switching effects and dose differences can't be ruled out. Small PWS trials of incretin therapies would be the logical follow-up.
Medicinen=—HumanSep 4, 2026 - Study · TirzepatideWeak / none
Adjunctive Treatments for Patients with Type 1 Diabetes Using Automated Insulin Delivery Systems. A Narrative Review.
This narrative review draws on a thin evidence base — the authors themselves describe the underlying data as limited, mixing small randomized and observational studies. Off-label GLP-1 use in type 1 diabetes is a live clinical question, and the early signal here is directionally encouraging on weight, insulin dose, and time in range. Larger and longer trials are needed before the safety picture, especially around ketoacidosis, can be considered settled.
Diabetes technology & therapeuticsn=——Sep 4, 2026 - Study · TirzepatideSupported
Recent Advances in Glucagon-Like Peptide-1 Receptor and Melanocortin-4 Receptor Agonists for the Treatment of Obesity and Type 2 Diabetes.
A broad literature review that favors breadth over depth, pairing the mainstream incretin class with the smaller melanocortin-4 field best known for setmelanotide in genetic obesity. It offers no systematic search methodology or pooled analysis, so it is best read as a mechanism-and-landscape primer. The efficacy characterizations are consistent with the published trial record.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolismen=——Sep 4, 2026 - Study · TirzepatideSupported
Glucagon-Like Peptide-1 Receptor Agonists for Obstructive Sleep Apnea: A Review.
A measured synthesis from an otolaryngology vantage point, anchored by six meta-analyses and the SURMOUNT-OSA phase 3 program, so the core efficacy signal is solid. The honest caveats are what make it worth reading: GLP-1 RAs trail CPAP head-to-head on AHI reduction, cardiovascular outcome benefits in OSA are unproven, and weight regain after discontinuation is the norm. The weight-independent mechanisms discussed — carotid body signaling, leptin pathways, inflammasome suppression — are preclinical and should be read as hypotheses. As a review it adds framing rather than new data, but the framing is the story: sleep apnea pharmacotherapy is now a real category, with tirzepatide holding the only approval.
JAMA otolaryngology-- head & neck surgeryn=——Sep 3, 2026 - Study · TirzepatideSupported
Glucagon-like Peptide-1 Receptor Agonist-Associated Injection Site and Dermatologic Reactions.
A useful cross-agent comparison of a side-effect category that gets less attention than nausea and GI complaints, with real numbers behind it. The FAERS data carry the usual caveats: reports are voluntary, lack denominators, and reporting rates are skewed by drug age, media coverage, and formulation differences — so the between-drug percentages rank report proportions, not true incidence. The authors themselves call for prospective studies to pin down actual risk rates. Still, for injection-site reactions specifically, the practical takeaway — common, usually mild, rarely a reason to stop — is well supported.
Clinics in dermatologyn=——Sep 3, 2026 - Study · TirzepatideMixed
Postmarketing Safety Signals and Medication-Use Risks of GLP-1-Based Therapies in Diabetes and Obesity: A Multi-Source Pharmacovigilance and Regulatory Evidence-Mapping Study.
This is a signal-prioritisation exercise, not a risk estimate, and the authors say so explicitly: spontaneous-reporting data cannot yield incidence, causality or comparative risk. The notable pattern is how much of the reported burden is medication-use error rather than classic pharmacology, with incorrect dose administered, extra dose administered and off-label use among the most common terms. Tirzepatide's share reflects uptake and reporting behaviour as much as anything intrinsic to the molecule. Read it as a map of where postmarketing attention is concentrated.
Diabetes, obesity & metabolismn=——Sep 3, 2026 - Study · TirzepatideMixed
Where the Future Lies: GLP-1 Receptor Agonists as Therapeutics for Dermatologic Comorbidities.
The authors' framing is the interesting part: they suspect the benefit in skin disease comes from correcting metabolic dysfunction and systemic inflammation rather than from any direct action on the skin. The underlying evidence is a mix of trials, observational studies and real-world analyses of varying quality, so this reads as a supported hypothesis rather than a settled indication. No GLP-1 agent carries a dermatologic approval, and the review proposes a conceptual model for future work.
Clinics in dermatologyn=——Sep 2, 2026 - Study · TirzepatideSupported
Integrating the liver into the cardiovascular-kidney-metabolic syndrome: pathophysiology and therapeutic implications.
The most actionable point is diagnostic rather than pharmacological: the authors want noninvasive fibrosis scoring used routinely in high-risk kidney-disease cohorts. On drugs, they read the recent trial set as evidence that incretin agents act across the whole cardiovascular-renal-hepatic-metabolic spectrum rather than on a single organ. Nomenclature is explicitly unsettled here, so the acronym itself should be regarded as provisional.
Current opinion in nephrology and hypertensionn=——Sep 2, 2026 - Study · TirzepatideMixed
Multi-Database Pharmacovigilance Analysis of Gastroesophageal Reflux Disease Associated with GLP-1 Receptor Agonists: A Cross-National Signal Validation Study.
The strength here is replication: the same directional signal appears in Western and Asian reporting systems, using an active comparator rather than the whole database, which blunts some of the usual disproportionality artefacts. The weakness is inherent to the method — spontaneous reporting captures what gets reported, not incidence, and the JADER counts (19 versus 16 cases) are far too small to carry the reported 4.76-fold estimate on their own. For readers tracking GLP-1 tolerability, reflux belongs on the list of gastrointestinal effects to watch alongside nausea and delayed gastric emptying, particularly at higher doses and in older users.
Gut and livern=——Sep 2, 2026 - Study · TirzepatideSupported
The Evolution of Medications for Obesity Management.
A narrative review rather than a systematic one, so study selection reflects the authors' judgment and no pooled estimates are offered. Its value is as a readable synthesis of how the field moved past a history of market withdrawals to the current incretin class, with headline efficacy figures that align with the pivotal trials. Useful orientation; no new data.
JGH open : an open access journal of gastroenterology and hepatologyn=——Sep 1, 2026 - Study · RetatrutideSupported
Pharmacological management of obesity: Current landscape and emerging therapies.
A serviceable landscape review rather than new data. Its value is the pipeline framing: the cagrilintide-semaglutide combination and retatrutide are positioned as the agents expected to narrow the efficacy gap with bariatric surgery, while oral and longer-acting formulations are the adherence play. The regional guideline detail is a reminder that staging conventions and access differ considerably by market. Claims about approaching surgical efficacy rest on trial weight-loss percentages, not on head-to-head outcome data.
Indian journal of pharmacologyn=——Sep 1, 2026 - Study · RetatrutideMixed
Incretin-based therapies in diabetic kidney disease: toward integrated cardio-kidney-metabolic disease modification.
The evidence gradient is the point worth carrying away: semaglutide has a dedicated hard-outcome kidney trial behind it, while the kidney case for tirzepatide and retatrutide currently rests on weight and metabolic endpoints plus mechanistic reasoning. This is a narrative review from a national study group, so it reflects a considered clinical position rather than a systematic quantitative synthesis, and the mechanistic sections lean on translational work that has not been confirmed in humans. Readers following the newer co-agonists should note that renal benefit is anticipated, not yet demonstrated.
Kidney research and clinical practicen=——Sep 1, 2026 - Study · TirzepatideWeak / none
Tirzepatide non-response with subsequent semaglutide response in class 2 obesity.
A single case, so it establishes that a tirzepatide non-responder can respond to semaglutide - not how often that happens or why. The proposed GIP receptor mechanism is inference from the literature rather than anything measured in this patient, and the authors themselves flag that the HOMA-IR threshold idea needs prospective testing. Useful as a counterweight to the assumption that the dual agonist is universally the stronger choice, which the head-to-head trial data supports only on average.
JCEM case reportsn=—HumanSep 1, 2026 - Study · TirzepatideSupported
Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate-Data Bayesian Longitudinal Meta-Analysis.
A Bayesian re-analysis of aggregate timepoint data rather than individual participant records, which limits how finely predictors can be examined - the signals for initial weight loss magnitude and for behavioural support both had credible intervals crossing zero. The authors are explicit that anything past 52 weeks is a linear extrapolation, so the 15-month return-to-baseline figure is a model output, not an observation. Even with those caveats, the direction and speed of regain are consistent with what individual discontinuation trials have reported.
Endocrinology, diabetes & metabolismn=—HumanSep 1, 2026 - Study · RetatrutideSupported
Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.
An Annals of Internal Medicine update with declared funding of none, adding 14 new randomised trials and roughly 11,000 participants to the prior version - about as authoritative a synthesis as this field currently has. The key limitation is stated plainly by the authors: heterogeneity ruled out pooled quantitative synthesis, so the percentage figures come from individual trials rather than a single meta-analytic estimate and should not be lined up as a strict ranking. Safety reporting across trials was inconsistent, which matters most for the newest multiagonists where exposure is still short.
Annals of internal medicinen=——Sep 1, 2026 - Study · TirzepatideSupported
Glycemia-based predictors of T2D development in adults with obesity and prediabetes: SURMOUNT-1 post hoc analysis.
Post hoc analysis of the SURMOUNT-1 prediabetes cohort, so the predictive-criteria comparison is exploratory and was not a prespecified endpoint. The one-hour OGTT threshold had high sensitivity but only 25 percent specificity, meaning it flags many people who would not have progressed. The tirzepatide risk reduction is consistent across all three criteria and matches the headline three-year SURMOUNT-1 result. SURMOUNT-1 was sponsored by Eli Lilly, and several authors are company employees.
Journal of the Endocrine Societyn=—HumanSep 1, 2026 - Study · TirzepatideWeak / none
GLP-1 and GLP-1/GIP receptor agonist medication use and self-reported outcomes in individuals with lipedema: Results from a large online survey.
Large cross-sectional online survey, which gives it reach but not rigor: respondents self-selected, outcomes are recalled rather than measured, and people who felt better on medication were more likely to keep taking it. The PROMIS-10 gaps between current and never-users are a few points on a scale where five points is usually the meaningful threshold. Tirzepatide was the most common agent but results are pooled across the class, so no drug-specific conclusion is possible. A reasonable hypothesis-generating signal for a condition with few pharmacological options.
Obesity pillarsn=——Sep 1, 2026 - Study · TirzepatideSupported
Weight loss outcomes with tirzepatide in women with and without self-reported polycystic ovary syndrome.
The reassuring finding — PCOS does not appear to blunt tirzepatide's weight response — is worth having, since PCOS is usually described as making weight loss harder. But the 10-month comparison rests on 40 women with PCOS and 397 without, out of a starting cohort of 54,114, so attrition and survivor bias dominate that timepoint and the confidence interval spans -22.4 to -16.4 percent. PCOS status was self-reported, not chart-confirmed, and the cohort comes from a commercial weight-management service. The digital-engagement finding is observational and cannot separate the tools from the kind of person who uses them.
Journal of the Endocrine Societyn=—HumanSep 1, 2026 - Study · TirzepatideWeak / none
Increasing skeletal muscle mass and strength during incretin-based weight loss.
This speaks directly to the muscle-loss concern that shadows incretin-based weight loss, and the grip-strength gains are a functional outcome, not just a body-composition estimate. But the design limits are substantial: an uncontrolled, retrospective case series from one clinic, with muscle mass measured by bioelectrical impedance — a method with meaningful error, especially during rapid weight change. Testosterone therapy and structured resistance training are each capable of producing these gains on their own. Read this as a proof-of-concept that muscle can be protected during tirzepatide-driven weight loss under an intensive multimodal program, not as evidence about tirzepatide itself.
Obesity pillarsn=—HumanSep 1, 2026 - Study · TirzepatideWeak / none
Inflammation-mediated facial nodules to compounded tirzepatide.
Case-report-level evidence, and the abstract is not available, so we are working from the title and journal context. Still, the compounded-tirzepatide angle is directly relevant to our readers, many of whom encounter compounded and grey-market versions of these drugs, and adverse-event reports tied specifically to compounded product deserve tracking. A published rebuttal letter already contests the causal attribution, so this should be framed as a disputed early signal, nothing more.
JAAD case reportsn=—HumanSep 1, 2026 - Study · TirzepatideMixed
Patient Experiences and Safety Concerns Regarding GLP-1 Receptor Agonists for Obesity: A Cross-Sectional Survey in Jeddah, Saudi Arabia.
A single-city survey with descriptive statistics, so it says nothing about how well these drugs actually work — but it is a useful window into how patients experience them. The standout patterns: longer duration of use tracked with higher perceived safety, and tirzepatide users stayed on therapy longer than semaglutide users. The affordability and information-gap findings echo what we see in community discussions well beyond Saudi Arabia. File under real-world use, not efficacy.
Saudi medical journaln=——Sep 1, 2026 - Study · TirzepatideMixed
Causes and consequences of discontinuation of GLP1RAs or tirzepatide.
Real-world persistence on these drugs is poor, and this review is a careful account of what that gap between prescription and continuation costs patients. Its central caution - that stop-start cycling may carry its own cardiometabolic risk - is framed as a hypothesis, not a demonstrated effect. Directly relevant to our semaglutide and tirzepatide pages, where what happens after stopping is one of the questions readers ask most.
Nature reviews. Endocrinologyn=——Sep 1, 2026 - Study · TirzepatideSupported
Impact of GLP-1 receptor agonists on cardiovascular outcomes in heart failure with preserved ejection fraction (HFpEF): systematic review and meta-analysis.
HFpEF has long resisted drug therapy, so a pooled 27 percent reduction in the composite of death or heart-failure hospitalization is a meaningful signal for the GLP-1 class — five of the six included studies used semaglutide, one tirzepatide. The effect is driven by hospitalizations rather than mortality, and 4,043 patients across six heterogeneous studies is still a modest evidence base. With zero statistical heterogeneity and low risk of bias in the RCTs, though, the direction of the finding looks solid.
Clinical research in cardiology : official journal of the German Cardiac Societyn=—HumanSep 1, 2026 - Study · TirzepatideSupported
Liver Fat Changes in Patients With Type 2 Diabetes by Presence of Genetic Hepatic Steatosis: A Post Hoc Analysis of SURPASS-3 MRI.
This post hoc look at SURPASS-3 MRI asks whether the strongest known genetic driver of fatty liver blunts tirzepatide's effect on liver fat. It does not appear to: reductions in liver fat content, weight, HbA1c, lipids, and liver enzymes held up across PNPLA3 genotype subgroups at 52 weeks. As an exploratory subanalysis it cannot carry the weight of a primary endpoint, but the consistency across genotypes is a reassuring signal for tirzepatide's liver effects.
Liver international : official journal of the International Association for the Study of the Livern=—HumanSep 1, 2026 - Study · TirzepatideWeak / none
Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown.
This is the clearest inventory yet of what "unique formulation" actually means in practice once the shortage exemption closed, and the answer is mostly additives with no stated rationale. The authors find little justification for the vitamin, amino acid, or stool-softener combinations, allow a pharmacological rationale for ondansetron while noting no evidence for giving it subcutaneously, and flag that sublingual and dissolving-tablet routes have not been shown to outperform the approved oral tablet. Fewer than one in five products documented a beyond-use date, which is a basic stability disclosure.
The Annals of pharmacotherapyn=——Sep 1, 2026 - Study · TirzepatideSupported
Weight Loss-Dependent Changes in Body Composition and Bone Health in People With Obesity and Type 1 Diabetes Treated With Liraglutide, Semaglutide, or Tirzepatide.
The signal worth noting here is what did not change: total bone mineral density held steady across a year of incretin-driven weight loss in a population with type 1 diabetes, a group already carrying elevated fracture risk. Lean mass did decline in proportion to total weight lost, which is consistent with the wider incretin literature and reinforces why resistance training and protein intake keep coming up in clinical discussion. This is an observational cohort of 70 people with no control arm, so read the results as reassuring rather than definitive.
Diabetes/metabolism research and reviewsn=—HumanSep 1, 2026 - Study · TirzepatideWeak / none
Resolution of anhedonia-like symptoms in patients treated for obesity with tirzepatide: A three-case series.
A three-case series flagging a possible neurobehavioral effect of high-dose tirzepatide, with symptom improvement reported after dose reduction. As an uncontrolled case series it raises a monitoring consideration rather than establishing incidence or causation.
Obesity pillarsn=—HumanSep 1, 2026 - Study · TirzepatideSupported
Tirzepatide and SGLT2 Inhibitors for Heart Failure With Preserved Ejection Fraction and Obesity: Entering a New Cardiometabolic Therapeutic Era.
A synthesis of trial and mechanistic evidence positioning tirzepatide within obesity-related HFpEF management, drawing on the SUMMIT trial's reported effects on weight, epicardial fat, and symptom scores. The authors are careful to note that cross-agent comparisons and combination therapy remain unproven in dedicated trials.
Endocrinology, diabetes & metabolismn=——Sep 1, 2026 - Study · TirzepatideMixed
Real-world treatment satisfaction and experience with once-weekly tirzepatide: Insights from prescribing physicians and people with obesity or overweight.
This is a cross-sectional survey capturing self-reported satisfaction and prescribing experience with tirzepatide, not a controlled outcomes study. Satisfaction data are inherently subjective and vulnerable to selection and reporting biases, and the analysis was industry-relevant secondary survey data. It usefully describes real-world experience with tirzepatide while carrying limited weight as evidence of clinical benefit.
Obesity pillarsn=—HumanSep 1, 2026 - Study · SemaglutideMixed
Changes in food cravings, dietary quality, body composition, and dietary intake during GLP-1 receptor agonist therapy: The CRAVE study.
A small prospective cohort (n=28) tracking body composition and diet during semaglutide or tirzepatide therapy, notable for flagging estimated muscle-mass loss and unchanged diet quality. The sample is tiny with attrition, muscle mass was estimated by bioimpedance, and the authors themselves label the findings exploratory. Still a useful, honest signal on the nutrition and lean-mass gaps that can accompany pharmacologic weight loss.
Obesity pillarsn=—HumanSep 1, 2026 - Study · TirzepatideWeak / none
Understanding reasons for initiation and experience with tirzepatide among individuals with obesity or overweight: Results from the PERCEPTIONS survey.
Baseline data from the observational PERCEPTIONS survey capturing why 518 adults with obesity started tirzepatide and how they experienced it early on, with cost and insurance coverage the dominant barriers. This is descriptive, patient-reported, and cross-sectional, so it speaks to real-world motivations and access rather than efficacy. Note the industry sponsorship context typical of SURMOUNT-adjacent work; still, it is useful signal on the lived experience and market friction around tirzepatide.
Obesity pillarsn=—HumanSep 1, 2026 - Study · TirzepatideWeak / none
Exercise-induced anaphylaxis with a cofactor of GIP/GLP-1 receptor agonist: A case report.
This brief case report describes a patient who developed exercise-induced anaphylaxis after starting the dual GIP/GLP-1 receptor agonist tirzepatide, with resolution of the reactions after tirzepatide was discontinued. The 'dechallenge', symptoms improving on stopping, is suggestive of a temporal link, but this is a single case with no rechallenge and no mechanism established, the weakest evidence tier. Exercise-induced anaphylaxis is typically multifactorial and cofactor-dependent, so tirzepatide's precise role is uncertain. Its value is signal-raising: clinicians seeing new exercise-associated allergic reactions in a patient recently started on tirzepatide have a reason to consider the drug as a possible cofactor. It says nothing about how common such a reaction might be, and should not shape general expectations of the drug.
The journal of allergy and clinical immunology. Globaln=—HumanSep 1, 2026 - Study · SemaglutideWeak / none
Micronutrient risk with GLP-1 receptor and dual incretin agonists in obesity: Mechanistic pathways, clinical signals, and a monitoring framework.
This narrative clinical review examines whether GLP-1 and dual GIP/GLP-1 receptor agonists, the drug class that includes semaglutide and tirzepatide, raise the risk of micronutrient deficiencies during long-term weight-loss treatment. Drawing on dietary studies, cohorts, and pharmacovigilance reports rather than trials, the authors argue that reduced food intake, less dietary variety, gastrointestinal intolerance, delayed gastric emptying, and rapid weight loss can converge on vulnerabilities in iron, vitamin B12, vitamin D, calcium, magnesium, zinc, and others. They stress that most abnormalities reported so far are subclinical or indirect, with clinically meaningful effects likely confined to higher-risk individuals. The abstract does not name specific agents, so this is class-level context. For semaglutide and tirzepatide readers, the practical value is a monitoring framework, not evidence of a defined deficiency rate.
Obesity pillarsn=——Sep 1, 2026 - Study · TirzepatideWeak / none
Impact of tirzepatide on systemic arterial stiffness assessed by cardio-ankle vascular index in individuals with obesity complicated by type 2 diabetes: A retrospective cohort study in Japan.
This is a small retrospective observational cohort (24 adults with obesity and type 2 diabetes, single-center, Japan) tracking arterial stiffness — measured by the cardio-ankle vascular index (CAVI) — over a median 12.7 months of weekly tirzepatide (5–15 mg). Researchers reported that tirzepatide was associated with significant reductions in CAVI (median 8.5 to 7.8) alongside falls in BMI, HbA1c, fat mass and, notably, skeletal muscle mass, with larger BMI reductions at higher doses. Several findings were only trends (urinary albumin reduction, dose-related CAVI change). The design caveats dominate interpretation: no control group, only 24 participants, two-thirds switched from other GLP-1 agents, and CAVI improvement tracks closely with weight and glucose changes, so an independent vascular effect can't be isolated. The muscle-loss signal is the practical flag the authors themselves raise. Read as a small hypothesis-generating cohort, not evidence of a distinct vascular benefit.
Obesity pillarsn=—HumanSep 1, 2026 - Study · TirzepatideSupported
Association of tirzepatide with changes in OSA-related measures based on baseline characteristics - post hoc analyses of SURMOUNT-OSA.
The underlying trials were randomised, double-blind and 52 weeks long, which gives these subgroup readings a solid foundation, and the consistency across five different baseline splits is the substantive finding. The authors label the work descriptive and hypothesis-generating for good reason: post hoc subgroup analyses are not powered for the comparisons they make and cannot support claims about who responds best. The author list includes Eli Lilly affiliations, consistent with sponsor-conducted analysis of the SURMOUNT-OSA program (NCT05412004).
Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicinen=—HumanAug 31, 2026 - Study · TirzepatideMixed
From adiposity to multisystem morbidity: the case for weight loss as disease modification.
The useful contribution here is the honest map of where the randomised evidence exists and where it does not: the incretin trial programme has produced hard outcome data for a handful of conditions and left most of the multisystem burden of obesity under-investigated. This is a narrative review rather than a quantitative synthesis, so the causal claims rest on the authors' triangulation judgement, and reviews by senior trialists in this field commonly carry industry advisory relationships worth checking in the declarations. Readers should note the framing distinction the paper draws between weight loss as a marker and weight loss as the mechanism of benefit, which the authors flag as still unresolved and dependent on mediation analyses yet to be done.
The lancet. Diabetes & endocrinologyn=——Aug 27, 2026 - Study · TirzepatideWeak / none
Tirzepatide as a possible trigger of bullous pemphigoid: A case report.
A single case report in JDDG, the weakest design for linking a drug to an adverse event: it can raise a question but cannot speak to how often this happens or whether the drug caused it. Bullous pemphigoid has an established association with other diabetes agents, notably DPP-4 inhibitors, which makes an incretin-era report worth logging. Without full text, the timing, any rechallenge and other exposures are unknown, so readers should regard it strictly as a hypothesis.
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDGn=—HumanAug 27, 2026 - Study · TirzepatideMixed
Glucagon-Like Peptide 1 Receptor Agonists, Mortality, and Cardiovascular Outcomes in Serious Mental Illness.
A target-trial emulation in JAMA Psychiatry using a new-user, active-comparator design, which is the right choice for observational data of this kind, and a direction consistent with randomized cardiovascular results for semaglutide. The one-year mortality gap, close to a halving, is larger than any randomized trial has produced and points to residual confounding in who is started on which drug rather than a clean pharmacological effect. The semaglutide and tirzepatide findings sit in exploratory subgroups, not the prespecified primary outcome, and the authors themselves call for randomized confirmation.
JAMA psychiatryn=—HumanAug 26, 2026 - Study · TirzepatideMixed
Nonscarring Alopecia in Adults Treated With GLP-1s: A Propensity Score Matched TriNetX Cohort Study.
A retrospective propensity-matched TriNetX cohort: strong on sample size, weak on controlling who gets prescribed these drugs and who gets a dermatology code entered. The null result for alopecia areata is a useful negative control, and the lower follow-up BMI among those with hair loss fits the authors' reading that rapid weight loss itself accounts for much of the effect. Coding-based outcomes and unmeasured confounding mean this shows an association rather than a drug-specific mechanism, and telogen effluvium is typically self-limited.
The Laryngoscopen=—HumanAug 26, 2026 - Study · TirzepatideSupported
Trends in Cost of Care With Tirzepatide in Adults Aged Over 55 Years With Obesity or Overweight Without Diabetes: A Matched Cohort Analysis.
Methodologically careful for a claims study — propensity matching, inverse-probability-of-censoring weights and pairwise censoring all address the differential-follow-up problem that usually wrecks this design. Two caveats carry weight: the cost offset applies to people who stay on therapy, which selects for tolerability and adherence, and the author list includes Eli Lilly affiliation, so the Medicare-programme framing is not disinterested. The 12- to 18-month medical-cost component was only borderline significant (p = 0.065). It is an economic argument, not a clinical outcomes finding.
Diabetes, obesity & metabolismn=—HumanAug 24, 2026 - Study · TirzepatideMixed
Responders Vs. Non-Responders or How to Predict the Response to GLP-1 or GLP-1/GIP Receptor Agonist Therapy.
A clear-eyed review that resists the pharmacogenomics hype: it notes a large GWAS linking GLP1R variation to weight-loss efficacy and GIPR variants to nausea and vomiting with tirzepatide, then flags those findings as single-cohort, self-reported and unreplicated. Narrative review, no systematic search, so read the predictor list as a research agenda rather than a hierarchy of evidence. The practical takeaway — early on-therapy response is the most defensible individualising signal — is modest and probably right.
Diabetes, obesity & metabolismn=——Aug 23, 2026 - Study · SemaglutideMixed
GLP-1 and dual GIP/GLP-1 receptor agonists' psychopharmacology and putative neuropsychiatric associated effects: a Bradford Hill-informed, systematic, evaluation.
This is a structured causal-inference review rather than new trial data, and its main value is discipline: it sorts a noisy pharmacovigilance literature through the Bradford Hill criteria instead of tallying case reports. The authors land where most regulators have — plausible mechanisms, insufficient proof of causation — which is a meaningfully calmer read than headlines about GLP-1s and suicidality. As a review, it cannot resolve confounding by indication; obesity and diabetes themselves carry psychiatric comorbidity. Worth reading as a map of open questions, not a safety verdict.
Current psychiatry reportsn=——Aug 21, 2026 - Study · TirzepatideMixed
Trends in utilization of glucagon-like peptide‑1 receptor agonists, sodium-glucose cotransporter‑2 inhibitors, and metabolic bariatric surgery in U.S. Adults with diabetes and obesity.
This is market-structure data rather than an efficacy study, and it quantifies two things the field discusses anecdotally: the near-total shift of metabolic care toward incretin drugs, and how leaky real-world use is — roughly half of initiators discontinue within a year. Tirzepatide leading on adherence and persistence is a competitive signal worth watching. Limitations are those of claims data: no reasons for discontinuation, no cash-pay or compounded use captured, and a privately insured population that may not generalize.
Diabetes research and clinical practicen=—HumanAug 20, 2026 - Study · TirzepatideSupported
Major Adverse Liver Outcomes With Tirzepatide and Injectable Semaglutide in Adults With Overweight or Obesity and Type 2 Diabetes.
This is observational target-trial emulation, not a randomized head-to-head, so residual confounding remains possible despite propensity matching. The sitagliptin benchmark is the useful detail: it shows the design had enough resolution to separate incretin users from a weaker comparator, and against that backdrop tirzepatide and semaglutide were indistinguishable on hard liver endpoints. Read the extra BMI reduction with tirzepatide as decoupled from liver outcomes over this window rather than as a signal of hepatic advantage. Seventeen months is short for cirrhosis progression, so the comparison stays open.
Obesity (Silver Spring, Md.)n=—HumanAug 19, 2026 - Study · TirzepatideSupported
Glucagon-Like Peptide-1 Receptor Agonists for Obstructive Sleep Apnea With and Without Continuous Positive Airway Pressure.
The effect size on apnea-hypopnea index is large and clinically meaningful, and the finding that it persists alongside CPAP use is the more interesting result for readers already on airway therapy. The evidence base is thin, though: five trials, under a thousand patients, and the tirzepatide data come largely from the SURMOUNT-OSA programme, so the pooled estimate is not independent of one sponsor's trials. Read this as consolidating an already-known signal rather than establishing a new one.
Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgeryn=—HumanAug 18, 2026 - Study · TirzepatideMixed
Prospective changes in sleep quality and depressive symptom burden following initiation of GLP-1-based therapies in patients with obesity: a real-world study.
This is a small single-arm observational cohort with no comparison group, so regression to the mean and expectation effects cannot be excluded. The interesting detail is that response tracked baseline symptom severity rather than percentage weight loss, which argues against a purely weight-mediated explanation for the mood and sleep changes. Read the results as hypothesis-generating, and weigh them against the larger randomized mood-safety datasets rather than in place of them.
Journal of endocrinological investigationn=—HumanAug 18, 2026 - Study · TirzepatideWeak / none
Depressed mood and suicidal thoughts reporting with GLP-1 receptor agonists in type 2 diabetes: A WHO VigiBase study.
This disproportionality analysis of the WHO VigiBase (2010-2024) examined reports of depressed mood and suicidal thoughts with GLP-1 receptor agonists in type 2 diabetes. Researchers reported signals for semaglutide, liraglutide and tirzepatide (adjusted reporting odds ratios of 2.13, 1.52 and 1.07 for depressed mood; 6.76, 2.43 and 3.39 for suicidal thoughts), with no signal for suicide attempts or completed suicide and low absolute reporting frequencies. Crucially, this is a spontaneous-reporting method: it detects reporting patterns, not incidence, and cannot establish causation, and concomitant antidepressant use and comorbid depression were more common in the GLP-1 group, pointing to underlying vulnerability or reporting effects. The authors themselves frame this as supporting monitoring in vulnerable patients rather than a uniform drug effect. Read it as a pharmacovigilance flag, not evidence that these peptides cause mood harm.
Journal of affective disordersn=——Aug 15, 2026 - Study · TirzepatideMixed
Evaluation of tirzepatide as an adjunct to buprenorphine for the treatment of opioid use disorder (TAB) trial: study design and rationale.
The addiction-medicine angle on GLP-1 drugs has so far run on animal data, observational cohorts, and anecdote; TAB is the first randomized trial to put tirzepatide to that test in opioid use disorder. The design is credible — double-blind, 9 sites, run by NIDA's Clinical Trials Network, with a hard retention endpoint. To be clear, this publication reports rationale and methods only; whether the drug moves retention or craving is an open question until the trial reads out. We flag it now because the readout will matter.
Contemporary clinical trialsn=——Aug 14, 2026 - Study · TirzepatideSupported
Evaluating the therapeutic impact of tirzepatide in people with partial lipodystrophy.
A small retrospective series, but in a rare disease with essentially one licensed option this counts as meaningful evidence. The insulin-requirement drop is the standout — a two-thirds median reduction in a population defined by extreme insulin resistance. No control group and single-center design mean the usual caveats apply, and the Cambridge group is appropriately measured in calling for prospective confirmation. Notable as tirzepatide's reach extends into rarer metabolic phenotypes well beyond common obesity.
The Journal of clinical endocrinology and metabolismn=—HumanAug 13, 2026 - Study · TirzepatideWeak / none
Association of Glucagon-Like Peptide-1 Receptor Analogues and Laryngeal Symptoms in Obese Adults.
A genuinely new side-effect signal from a very large matched records database, and one that fits plausibly with known GLP-1 effects on reflux and delayed gastric emptying. The design is retrospective and diagnosis-code-based, so confounding and detection bias — people on these drugs see doctors more often — could account for some of the effect. The tirzepatide null result is intriguing but should not be over-read; it may reflect the shorter time this drug has been on the market. One to note for readers tracking the fuller side-effect picture as these medications scale to tens of millions of users.
The Laryngoscopen=—HumanAug 12, 2026 - Study · TirzepatideSupported
From Pathobiology to Prescribing in Obesity-Driven HFpEF: A Systematic Review and Practical Therapeutic Framework.
This is a synthesis rather than new trial data, but it is a useful marker of where cardiology consensus is heading: incretin peptides are being written into the core HFpEF playbook, not the margins. The semaglutide claims rest on the STEP-HFpEF program and the tirzepatide claims on SUMMIT, both dedicated randomized trials, so the framework stands on reasonably firm ground. The proposed sequencing itself is the authors' judgment and has not been tested head-to-head. Worth covering as a signal of how quickly these agents have moved into mainstream heart-failure thinking.
Current problems in cardiologyn=——Aug 12, 2026 - Study · TirzepatideSupported
Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis.
Post hoc biomarker work, but from a randomized placebo-controlled trial with 72-week follow-up and a notably broad panel — this is the most comprehensive mechanistic look at tirzepatide's cardiovascular profile to date. The hsCRP and IL-6 reductions are striking in magnitude and dose-ordered, which strengthens the causal read. Biomarkers are not outcomes; the definitive answer awaits SURMOUNT-MMO's hard-endpoint results. Still, the consistency across inflammation, endothelial, and hemostatic pathways is a substantive signal worth reporting.
Journal of the American College of Cardiologyn=—HumanAug 11, 2026 - Study · TirzepatideSupported
Tirzepatide Persistence and Associated Changes in Clinical Outcomes in US Adults With Obesity or Overweight: A 6-Month Claims Database Analysis.
This large claims analysis puts real-world numbers on tirzepatide persistence: 68 percent of initiators stayed on therapy through six months, better than figures often reported for the GLP-1 class. The 10.5 percent average weight reduction among persistent users tracks reasonably close to trial results, though it comes from only 808 people with usable before-and-after weights — a small, possibly unrepresentative slice. Worth noting the author list includes Eli Lilly-affiliated researchers, standard for this kind of manufacturer-sponsored database work.
Diabetes, obesity & metabolismn=—HumanAug 10, 2026 - Study · TirzepatideSupported
Real-world effectiveness of tirzepatide among youth with type 2 diabetes and/or obesity: a multicenter analysis.
Real-world pediatric data on tirzepatide is scarce, which makes this small multicenter cohort notable despite its limitations. Blood-sugar improvements were the clearer signal — HbA1c fell meaningfully and insulin doses came down — while weight changes were modest at a median 102-day first follow-up. Nearly four in five patients had prior GLP-1 exposure, so these are largely second-line results; without a comparison group, the findings are associations rather than proof of effect.
Journal of pediatric endocrinology & metabolism : JPEMn=—HumanAug 10, 2026 - Study · SemaglutideMixed
Perioperative management of GLP-1 receptor agonists: a structured narrative review with considerations relevant to neurosurgical patients.
A practical safety review for the growing number of GLP-1 users heading into surgery, with a focus on neurosurgical settings where aspiration carries outsized consequences. The evidence is two-sided: gastric retention is reliably more common on these agents, particularly during dose escalation or active GI symptoms, yet population-level data have not shown more aspiration events. The authors are candid that neurosurgery-specific evidence is thin and frame their guidance as expert extrapolation rather than formal recommendations — a caveat worth keeping in view.
Journal of endocrinological investigationn=——Aug 10, 2026 - Study · TirzepatideMixed
Changes in recorded background glucose-lowering therapy after initiation of a GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist in adults with type 2 diabetes.
This Polish EHR study tracks what happens to background diabetes medications after patients start semaglutide, tirzepatide, or older GLP-1 agents. Additional glucose-lowering substances were recorded more often than they were removed, with tirzepatide starters showing the lowest rate of added therapy at 20.4 percent versus 52.9 percent for dulaglutide. The authors are appropriately careful: these are prescription-record patterns, not proof of actual exposure or a causal difference between agents.
Diabetes research and clinical practicen=—HumanAug 10, 2026 - Study · TirzepatideSupported
Predicted 10-Year Cardiovascular Disease Risk Reduction with Tirzepatide Use Over Three Years for Primary Prevention of Cardiovascular Disease in Obesity.
The strength here is the source, a large randomized, placebo-controlled trial running 176 weeks, which is rare territory for obesity drugs. The limitation is that the endpoint is a Framingham risk equation, not actual cardiovascular events, and post hoc analyses of surrogate scores tend to run ahead of what outcome trials later confirm. The authors' cross-check against REWIND, where predicted and observed effects roughly agreed, is a reasonable credibility test, but the definitive answer awaits the event-driven SURMOUNT-MMO trial. Several authors are affiliated with the manufacturer, which readers should weigh.
European journal of preventive cardiologyn=—HumanAug 10, 2026 - Study · TirzepatideSupported
Tirzepatide Use Is Associated with Reduced Risk of Carpal Tunnel Syndrome in Overweight and Obese Adults.
An unexpected corner of the tirzepatide story: carpal tunnel syndrome is linked to obesity and diabetes, so a drug that improves both could plausibly lower risk. The target-trial-emulation design and extensive sensitivity analyses are stronger than typical database work, but this remains retrospective claims-style data, where diagnosis capture and residual confounding can move hazard ratios of this size. The 0.82 hazard ratio against other GLP-1 agents is modest; the comparison against non-incretin drugs is the more convincing signal.
Clinical pharmacology and therapeuticsn=—HumanAug 10, 2026 - Study · SemaglutideMixed
GLP-1-Based Therapies in Pain Medicine: A Narrative Review and Expert Opinion on Obesity-Related Low Back and Knee Pain.
This is an expert-opinion narrative review, not new trial data, so it carries the weight of clinical judgment rather than fresh evidence. Still, it marks a notable shift: pain physicians are now openly debating whether to prescribe GLP-1 class drugs themselves. The authors are careful to position these agents as adjuncts to rehabilitation and standard pain care, not substitutes, and they flag possible anti-inflammatory and cartilage-related effects as promising but unproven.
Current pain and headache reportsn=——Aug 10, 2026 - Study · SemaglutideMixed
Glucagon-Like Peptide-1 Receptor Agonists and Related Incretin Therapies in Dermatology: Patient Selection and Shared Decision-Making.
A narrative review rather than new data, but useful as a window into how GLP-1 therapies are rippling into specialties far from diabetes care. The authors' framing is notably measured: the evidence in dermatology is still evolving, and they lean on shared decision-making rather than firm indications. The catalog of appearance-related effects, particularly facial volume loss and hair shedding, tracks closely with what the community has been reporting anecdotally.
Clinics in dermatologyn=——Aug 9, 2026 - Study · TirzepatideMixed
Impact of GLP-1 Analogue Therapy on Gastrointestinal Outcomes in Patients with Irritable Bowel Syndrome: A Real-World TriNetX Analysis.
The direction of this result runs against the common expectation that GLP-1 agonists worsen gut symptoms, which is what makes it worth a look. The absolute differences are small — roughly two to four percentage points — and the outcomes are diagnostic codes in health records, which capture what a clinician chose to document rather than what a patient actually experienced. Propensity matching cannot rule out that people prescribed these drugs differed in ways the data do not record, including care intensity. Regard it as a signal for a prospective study, not as evidence of benefit in IBS.
Digestive diseases and sciencesn=—HumanAug 8, 2026 - Study · TirzepatideSupported
Real-World Effectiveness and Treatment Patterns of Tirzepatide in a Large UK Digital Health Cohort.
Real-world GLP-1 results usually undershoot the trials; this enormous digital-pharmacy cohort is notable for how little it does. Two findings stand out: consistent ordering cadence tracked with better outcomes, and clinically meaningful weight loss was frequently achieved at intermediate doses — relevant to the dose-escalation debates playing out in community forums. Caveats apply: self-reported weights, a self-selected paying population, and heavy attrition by month twelve, so the 12-month figure reflects the people who stayed the course.
Diabetes, obesity & metabolismn=—HumanAug 6, 2026 - Study · TirzepatideSupported
Analysis of the efficacy and safety of liraglutide, semaglutide, and tirzepatide for the treatment of overweight and obesity: a systematic review and network meta-analysis.
This is the most current head-to-head-style comparison of the major weight-management incretins, and its ordering — tirzepatide first, high-dose semaglutide second — matches what the individual trials have suggested. The most practically useful finding is the tempered read on semaglutide 7.2 mg: consistently ranked above 2.4 mg, but with an average incremental benefit the authors themselves call modest, and statistically clear mainly in the diabetes subgroup. Rankings rest on indirect comparison with considerable heterogeneity, so direct head-to-head trials remain the missing piece.
Journal of endocrinological investigationn=—HumanAug 6, 2026 - Study · TirzepatideSupported
Tirzepatide and the risk of atherosclerotic cardiovascular events: population based cohort study.
Tirzepatide's dedicated cardiovascular outcomes trial has not yet read out, so this carefully built claims-database study is the best available preview — and it comes from a Harvard group whose methods have been benchmarked against randomized trials. A hazard ratio of 0.68 for major cardiovascular events would put tirzepatide in the same territory as semaglutide's SELECT result, and the negative-control checks came back clean. It remains observational, and the unexpected infection-related findings deserve replication, but this is a substantial signal ahead of the definitive trial.
BMJ (Clinical research ed.)n=—HumanAug 5, 2026 - Study · RetatrutideMixed
The role of GLP-1 and GIP receptor agonists in the treatment of diabetes and obesity.
A tidy reference review of incretin pharmacology from a veteran of the drug-mechanism literature. The most useful sections for our readers explain the molecular engineering behind long-acting peptides — fatty acid acylation piggybacking on albumin — and lay out the current approval map, with retatrutide still in trials. Nothing new here, but a well-organized primer on how this drug class actually works.
Pharmacological researchn=——Aug 5, 2026 - Study · TirzepatideMixed
Safety and efficacy of glucagon like peptide-1 receptor agonism-based therapies in end-stage renal disease: A systematic review and meta-analysis.
End-stage renal disease is exactly the population excluded from the pivotal incretin trials, so any pooled data here fills a genuine gap. The effect sizes look smaller than in the general obesity trials and the heterogeneity at twelve months is high enough to blunt confidence in the point estimates. The authors call their own findings hypothesis-generating and ask for prospective randomised trials, which is the right reading of 388 patients drawn largely from observational reports.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologistsn=—HumanAug 4, 2026 - Study · TirzepatideSupported
GLP-1 Receptor Agonist Therapy for Obesity Under Japan's Optimal Use Guideline: A Prospective Real-World Study of Lifestyle Pre-Treatment, Time-Limited Treatment Cap, and Post-Cessation Regain.
This is a natural experiment in what happens when a regulator forces discontinuation, and the answer is unambiguous: the weight came back fast. The six-month lifestyle prerequisite also looks counterproductive for post-surgical patients, most of whom gained weight while waiting. With 104 patients and small numbers at the later time points, the precision is limited, but the direction of the post-cessation curve is hard to argue with and speaks to obesity as a chronic condition rather than a fixed course of therapy.
Diabetes, obesity & metabolismn=—HumanAug 4, 2026 - Study · TirzepatideSupported
Overweight and obesity induce Toll-like receptor 2-induced Type I IFN signaling.
The dissociation is the interesting part. Tirzepatide lowered inflammatory signalling while leaving LDL unchanged, which means the anti-inflammatory effect is not simply a downstream consequence of lipid improvement. Metformin separated the two further by acting without any weight or LDL change at all. This is mouse and cell-culture work identifying a pathway, not a clinical outcome study, and tirzepatide appears as one of three comparator arms rather than the primary subject.
npj metabolic health and diseasen=—AnimalAug 3, 2026 - Study · TirzepatideWeak / none
Peripheral nerve complications from medications utilised for weight loss: a systematic review.
The evidence base here is case reports, so incidence cannot be estimated and confounding by rapid glycaemic correction is impossible to separate from the drug itself. What the pattern does suggest is a rate-of-change signal rather than a drug-specific one: the median loss was more than a fifth of body weight in roughly five months. The authors recommend adequate nutritional status and avoiding ultrarapid HbA1c and weight decline, which is a reasonable precaution while prospective data are absent.
Journal of neurologyn=——Aug 3, 2026 - Study · TirzepatideSupported
Beyond Weight Loss: Tirzepatide as a Metabolic Disease-Modifying Strategy for Metabolic Dysfunction-Associated Steatohepatitis: A Narrative Review.
A narrative review rather than new data, but a competent synthesis of a genuinely active question. The load-bearing evidence it cites — SYNERGY-NASH, where tirzepatide showed steatohepatitis resolution and fibrosis improvement against biopsy endpoints — is real, though phase 2 scale. With resmetirom now on the market and semaglutide's own MASH data maturing, the incretin class is converging on liver disease from the metabolic side. Useful context piece; the caveats about durability and long-term safety are appropriately front and center.
Health science reportsn=——Aug 1, 2026 - Study · SemaglutideMixed
GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults.
A target-trial-emulation cohort associating GLP-1 receptor agonist use with lower short-term obesity-associated cancer incidence in nondiabetic adults, with semaglutide and tirzepatide analyzed as a subgroup. As an observational analysis it establishes association only, and the authors call for prospective trials to address causality.
Annals of oncologyn=—HumanAug 1, 2026 - Study · TirzepatideWeak / none
Tirzepatide in recurrent hypertriglyceridemia-mediated pancreatitis and type 2 diabetes: a case report.
This case report explores tirzepatide's use in a setting where incretin therapy is often withheld, describing a favorable course that the authors explicitly frame as association rather than causation. As a single-patient observation it is hypothesis-generating and should be read in that light.
Cardiovascular diabetology. Endocrinology reportsn=—HumanAug 1, 2026 - Study · TirzepatideWeak / none
Case report: Tirzepatide-associated morbilliform drug eruption and implications for rising glucagon-like peptide-1 agonist use.
A single case report of a skin eruption associated with tirzepatide offers a safety signal worth noting but carries limited evidentiary weight. It documents a possible adverse reaction rather than establishing incidence or causality.
JAAD case reportsn=—HumanAug 1, 2026 - Study · TirzepatideSupported
Real-world evaluation of the effectiveness and safety of tirzepatide in patients with obesity: a prospective study.
This prospective observational study reinforces trial findings by showing tirzepatide's reported effects on weight and cardiometabolic markers hold up in routine clinical practice. The single-arm real-world design and modest sample size mean it complements rather than replaces randomized evidence.
Clinical nutrition ESPENn=—HumanAug 1, 2026 - Study · TirzepatideWeak / none
Atypical Anorexia Nervosa Developed in a Patient with Severe Obesity and Type 2 Diabetes Following Sleeve Gastrectomy and Postoperative Treatment with Semaglutide and Tirzepatide.
A single case cannot establish causation, and this patient also underwent sleeve gastrectomy, making the peptides' specific contribution impossible to isolate. It is a useful safety-awareness signal that rapid weight loss regimens may coincide with disordered-eating psychopathology in susceptible individuals. Regard it as hypothesis-generating rather than as evidence of a defined risk.
Internal medicine (Tokyo, Japan)n=—HumanAug 1, 2026 - Study · TirzepatideMixed
Beyond weight loss: How metabolism in human adipocytes is shaped by GLP-1R agonists and dual GIPR/GLP-1R agonists.
A narrative review of preclinical adipocyte biology for GLP-1R and dual GIPR/GLP-1R agonists, with tirzepatide as the named dual agonist. It synthesizes mechanism-level animal and in vitro findings rather than clinical outcomes, and the authors themselves flag that these models may not translate to human adipose tissue. Readers can read it as background on possible tissue-level mechanisms, not as clinical evidence.
Pharmacological researchn=——Aug 1, 2026 - Study · TirzepatideWeak / none
Papular granuloma annulare associated with tirzepatide: A case report.
A single-patient case report noting papular granuloma annulare occurring alongside tirzepatide use. Case reports document a possible association but cannot establish causation, and no abstract detail was available to assess the clinical context. It is a useful safety-signal note rather than evidence of a consistent effect.
JAAD case reportsn=—HumanAug 1, 2026 - Study · TirzepatideMixed
Targeting the activin/myostatin - actrii pathway to preserve skeletal muscle mass in obesity: mechanistic insights and therapeutic perspectives.
A mechanistic review centered on the activin/myostatin-ActRII pathway and muscle-preserving strategies during obesity treatment. Tirzepatide and GLP-1 agonists appear mainly as the backdrop that motivates concern about lean-mass loss, with the bulk of the discussion devoted to activin-receptor blockade agents such as bimagrumab. Relevant to the ongoing conversation about muscle preservation, though the tracked peptide is peripheral to the review's focus.
Reviews in endocrine & metabolic disordersn=——Aug 1, 2026 - Study · SemaglutideMixed
Personalization of incretin therapy: can GLP-1 and GIP receptor polymorphisms influence therapy response?
A narrative review synthesizing pharmacogenomic data on how GLP1R and GIPR polymorphisms relate to variability in response to semaglutide and tirzepatide. The associations described are drawn largely from earlier genetic studies and remain hypothesis-generating; the authors note that population-specific prospective data are still limited. Useful as background on why individual responses differ, rather than as clinically actionable guidance.
Journal of the Endocrine Societyn=——Aug 1, 2026 - Study · TirzepatideSupported
Clinical Potential of GIP in Type 2 Diabetes and Obesity.
A mechanistic review that positions tirzepatide as the most potent incretin-based agent to date and explores the contribution of GIP receptor signaling to its metabolic effects. Tirzepatide is central to the discussion, though the review focuses on incretin biology rather than reporting new trial data. It is a solid background reference on how dual incretin agonism has been studied in metabolic disease.
Diabetes caren=——Aug 1, 2026 - Study · SemaglutideMixed
Association of Glucagon-Like Peptide-1 Receptor Agonists and Suicidality: A Systematic Review.
This systematic review of adverse-event reports found semaglutide and liraglutide associated with elevated reported odds of suicidal ideation, with tirzepatide showing a nonsignificant trend. Both tracked peptides are genuine subjects and the safety topic is important. Critically, the data are disproportionality signals from spontaneous reports and the authors state no causality is apparent, so this is a hypothesis, not a confirmed risk.
Obesity reviewsn=——Aug 1, 2026 - Study · SemaglutideSupported
Beyond weight loss: multisystem benefits of obesity medications.
This narrative review of obesity medications covers semaglutide and tirzepatide among many agents, summarizing multisystem benefits reported across RCTs and meta-analyses. Both peptides are genuine subjects but sit within a broad drug-class overview rather than a focused analysis. Useful context, though weight-loss-independent effects are described as accumulating rather than settled.
The lancet. Diabetes & endocrinologyn=——Aug 1, 2026 - Study · TirzepatideSupported
Effect of Tirzepatide on Health-Related Quality of Life in Japanese Patients With Obesity Disease: Patient-Reported Outcomes From the SURMOUNT-J Study.
Directly tirzepatide-specific evidence from SURMOUNT-J, the phase 3 randomized placebo-controlled trial in Japanese adults with obesity disease (without diabetes). This analysis reports prespecified quality-of-life outcomes over 72 weeks: both tirzepatide doses (10 and 15 mg) significantly improved weight-specific quality-of-life scores (IWQOL-Lite-CT physical, psychosocial and total composites) and the SF-36 physical-functioning domain versus placebo, with effects consistent across sex, BMI and age subgroups. Weight loss correlated with quality-of-life improvement, though modestly (correlations up to about -0.32). Strengths: randomized, placebo-controlled, prespecified endpoints, meaningful 72-week duration. Caveats worth noting: the sample is relatively small (201 participants) and specific to a Japanese population, patient-reported outcomes are subjective and vulnerable to unblinding effects in a trial where weight change is visible, and the correlations with weight loss are weak-to-moderate. A credible, positive quality-of-life data point for tirzepatide that fits the broader SURMOUNT program.
Diabetes, obesity & metabolismn=—HumanAug 1, 2026 - Study · TirzepatideMixed
Short-Term Combined Treatment With Tirzepatide and Metformin for Overweight/Obese Chinese Women With Polycystic Ovary Syndrome: A Prospective, Open-Label, Randomised Controlled Trial.
A small randomized controlled trial (60 women) testing low-dose tirzepatide added to metformin versus metformin alone in overweight/obese Chinese women with polycystic ovary syndrome (PCOS) — a directly tirzepatide-specific study extending the peptide into a reproductive-endocrine context beyond its diabetes and obesity base. Over 16 weeks the combination arm showed markedly greater weight loss (-10.4 vs -1.7 kg), larger reductions in BMI and visceral fat, and improvements in reproductive-endocrine parameters, with higher rates of menstrual-cycle recovery and pregnancy after switching back to metformin. The design is a genuine strength (randomized, prospective), but weigh it against real limits: it is small, open-label (no blinding, so expectation effects are possible), single-centre, short, and PCOS-specific to one population. The pregnancy-rate signal is intriguing but based on tiny numbers. This is a promising, well-scoped signal for tirzepatide in PCOS-related weight and metabolic outcomes, appropriately held as early rather than definitive.
Diabetes, obesity & metabolismn=—HumanAug 1, 2026 - Study · TirzepatideSupported
Glucagon-Like Peptide-1 Based Therapies and the Risk of Severe Gastrointestinal Motility Adverse Events: A Cohort Study.
A large, well-constructed active-comparator cohort (313,342 matched pairs) examining a real and above-the-fold safety question: severe gastrointestinal motility events — constipation, gastroparesis, bowel obstruction — with GLP-1-based therapies. Tirzepatide is explicitly included in the exposure arm, though most of the analysis is at the class level versus SGLT-2 inhibitors. The reported signal is consistent: a 37% relative increase in the composite outcome (HR 1.37, 95% CI 1.30–1.45), stable across agent, age, sex, BMI, frailty and opioid-use subgroups. The crucial framing, which the authors handle well, is absolute risk: even elevated, the event rate was about 1 per 100 person-years or less — roughly 1% — so the relative increase sits on a small base. The new-user, active-comparator design and propensity matching are methodological strengths that reduce (though cannot eliminate) confounding by indication. A credible, clinically useful safety data point that belongs on the risk side of the ledger, with the relative-versus-absolute distinction made plain.
Diabetes, obesity & metabolismn=—HumanAug 1, 2026 - Study · TirzepatideMixed
Glucagon-Like Peptide-1 Receptor Agonists and Risk of Systemic and Ocular Vascular Complications in Patients With Type 2 Diabetes and Diabetic Retinopathy.
A large propensity-matched cohort (173,216 adults with type 2 diabetes and pre-existing diabetic retinopathy — a high-risk group often excluded from trials) drawn from the TriNetX network. GLP-1 receptor agonist use, with semaglutide and tirzepatide among the six agents in the exposure definition, was associated over two years with lower risk of a broad range of vascular complications: myocardial infarction, heart-failure exacerbation, ischemic stroke, amputation, acute kidney injury and dialysis, and — notably for the retina — less progression to proliferative diabetic retinopathy, fewer retinal vein occlusions, and less neovascular glaucoma. Reassuringly for the ongoing NAION debate, this study found no association with NAION or retinal artery occlusion. Two caveats anchor the reading: semaglutide and tirzepatide are pooled within the class exposure, so agent-specific effects cannot be separated, and the observational design leaves room for confounding by indication despite matching. A meaningful data point on retinal and vascular outcomes, weighted associational.
American journal of ophthalmologyn=—HumanAug 1, 2026 - Study · TirzepatideMixed
Comparative Effects of Individual Glucagon-Like Peptide-1 Receptor Agonist-Based Medications on Direct Measurement of Body Composition Among Adults With Overweight or Obesity With or Without Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials.
A network meta-analysis of 43 randomized trials (3,379 participants) examining what GLP-1 receptor agonists do to body composition — not just scale weight, but fat versus lean tissue measured directly. It is agent-level, so both tracked peptides surface: subcutaneous semaglutide 1.0 mg weekly and tirzepatide 15 mg weekly are named, alongside liraglutide, as agents associated with statistically significant loss of lean mass from baseline (standardized mean differences roughly -0.50 to -1.09). The headline is nuanced and worth surfacing carefully: these drugs substantially reduced total body fat, fat mass, visceral and subcutaneous fat, and liver fat, but the lean-mass finding — especially at higher doses — is the clinically important caveat the muscle-preservation conversation has been circling. As meta-analytic RCT evidence this ranks well, though network meta-analyses depend on trial comparability and body-composition measurement varied across studies. A substantive, peptide-specific data point on the fat-versus-muscle question.
Diabetes, obesity & metabolismn=—HumanAug 1, 2026 - Study · TirzepatideMixed
Optic Ischaemic Neuropathy in Incretin-Based Therapy: A Comparative Analysis of Real-World Safety Data.
This is a pharmacovigilance study of a live safety question — the reported association between semaglutide and non-arteritic anterior ischemic optic neuropathy (NAION), an eye condition serious enough to have prompted European Medicines Agency review. Using the FDA Adverse Event Reporting System, the authors found a very strong disproportionality signal for semaglutide (355 reports; reporting odds ratio around 94) and smaller but significant signals for tirzepatide and liraglutide, while dulaglutide, exenatide and lixisenatide showed none — arguing against a uniform class effect. The central caveat is fundamental to the method: FAERS is a spontaneous-reporting database, so disproportionality signals reflect reporting patterns, not incidence, and cannot establish causation or absolute risk. Media attention and regulatory notoriety can inflate reporting for a drug like semaglutide. The authors say as much, calling for prospective, ophthalmologist-confirmed studies. Because side effects and risks belong above the fold on our peptide pages, this is worth surfacing — with disproportionality framed carefully as a hypothesis-generating signal.
Diabetes, obesity & metabolismn=——Aug 1, 2026 - Study · TirzepatideMixed
GLP-1 receptor agonist adjunct therapy stabilises Ramadan dysglycaemia in insulin-treated diabetes: a CGM-based study.
A small, focused observational study with a genuinely peptide-specific question: whether adding semaglutide (a GLP-1 receptor agonist) or tirzepatide (a GLP-1/GIP dual agonist) to insulin helps stabilize blood sugar during Ramadan fasting. Using continuous glucose monitoring, researchers compared matched groups of insulin-treated type 2 diabetes patients with and without the add-on peptides. The reported signal is sizeable — time in range 74.4% versus 36.8%, and roughly a 61% reduction in the post-iftar glucose excursion — with no increase in hypoglycemia and no discontinuations. Two important caveats temper the finding: the study is small (18 per arm, 54 total) and observational rather than randomized, so matching on age, HbA1c and BMI cannot fully rule out confounding, and it collapses two distinct drugs into one 'add-on' arm, so we cannot separate semaglutide's contribution from tirzepatide's. The finding is promising and mechanistically coherent, but the evidence weight is modest.
Diabetes research and clinical practicen=—HumanAug 1, 2026 - Study · TirzepatideWeak / none
Tirzepatide ameliorates cisplatin-induced acute kidney injury by restoring NAMPT/NAD + homeostasis and enhancing Pink1-Parkin-mediated mitophagy.
This preclinical study tested whether tirzepatide protects against cisplatin-induced acute kidney injury, using a mouse model plus cisplatin-injured human kidney (HK-2) cells and metabolomics. Researchers reported that tirzepatide pretreatment reduced kidney dysfunction, tubular and mitochondrial damage, and that it acted by boosting NAD+ via the enzyme NAMPT and activating the Pink1-Parkin mitophagy pathway; blocking NAMPT or autophagy removed the benefit. These are mechanistic findings in animals and cells, not clinical evidence, so they suggest a plausible pathway rather than a therapy for chemotherapy-related kidney injury in people. The pretreatment design also differs from real-world timing. It is a coherent mechanistic story that adds tirzepatide to the broader interest in GLP-1/GIP agents' organ-protective effects, but human studies would be required before any clinical reading.
Biochemical pharmacologyn=—AnimalAug 1, 2026 - Study · SemaglutideMixed
Impact of incretin therapies on biochemical and imaging outcomes in metabolic dysfunction-associated steatotic liver disease.
This meta-analysis of 24 randomised trials (2,158 adults) assessed incretin therapies, GLP-1 receptor agonists and emerging dual agonists, in metabolic dysfunction-associated steatotic liver disease. Compared with placebo, the pooled estimates showed reductions in the liver enzymes ALT and AST and in liver fat, with greater enzyme improvement versus insulin and improved non-invasive fibrosis markers. Notably, steatohepatitis resolution was greater than placebo but not insulin, and effects on histologic fibrosis remained inconclusive with wide confidence intervals for liver fat. The abstract does not name specific agents, so this reads as class-level evidence for the family that includes semaglutide and tirzepatide. Benefits appeared larger in patients with diabetes. For readers, this supports a biochemical and imaging benefit signal in fatty liver disease while leaving the harder endpoint, fibrosis reversal, unproven; the authors call for larger, longer trials.
American journal of preventive cardiologyn=—HumanAug 1, 2026 - Study · SemaglutideMixed
Hypertensive disorders of pregnancy and GLP-1 receptor agonist timing: a systematic review and meta-analysis.
Semaglutide and tirzepatide are among the class members pooled here, but the analysis reports a class-level estimate rather than peptide-specific results. The pooled odds ratio was non-significant and the constituent studies conflicted, so the finding is best regarded as inconclusive. Larger prospective studies are needed before drawing conclusions about pregnancy risk.
Endocrinen=—HumanJul 31, 2026 - Study · TirzepatideSupported
Effect of Medications for Type 2 Diabetes on Cardiovascular Events and Mortality: A Comprehensive Pairwise and Network Meta-Analysis.
A large network meta-analysis placing tirzepatide among the diabetes agents associated with reduced cardiovascular events and mortality, with moderate-to-high certainty of evidence. Tirzepatide is one of several drug classes compared, so the finding is class-contextual rather than tirzepatide-specific.
Diabetes, obesity & metabolismn=—HumanJul 30, 2026 - Study · TirzepatideWeak / none
Abrupt Smoking Cessation Due to Sensory Aversion Following Tirzepatide Initiation.
A single case report noting abrupt smoking cessation linked to sensory aversion after tirzepatide initiation, adding to interest in GLP-1 agents and addictive behaviors. It is an isolated observation and does not establish a reproducible effect.
The primary care companion for CNS disordersn=—HumanJul 30, 2026 - Study · TirzepatideMixed
Concurrent initiation of tirzepatide and biologics improves patient-reported outcomes in obese psoriatic arthritis: a propensity score-matched study.
This propensity score-matched study associates concurrent tirzepatide and biologic initiation with improved disease-activity and patient-reported outcomes in obese psoriatic arthritis. With only 31 treated patients and a matched-control rather than randomized design, the findings are promising but should be regarded as preliminary.
RMD openn=—HumanJul 30, 2026 - Study · TirzepatideSupported
Low-Dose Tirzepatide for Obesity: Comparative Efficacy of 2.5 mg Versus 5 mg in Non-Diabetic Japanese Adults.
This prospective non-randomized cohort compared two low maintenance doses of tirzepatide and found comparable weight loss with better tolerability at 2.5 mg. The non-randomized, shared-decision dosing design introduces potential confounding, so the dose-equivalence signal should be regarded as preliminary.
Diabetes, obesity & metabolismn=—HumanJul 28, 2026 - Study · SemaglutideMixed
Incretin-based therapies, alcohol and tobacco use, and acute substance-related events: emerging implications for cardiovascular medicine.
This narrative review pulls together randomized and observational evidence linking semaglutide to reduced alcohol-related outcomes, with weaker signals for tobacco and other substances. As a synthesis rather than primary data, it reflects an evolving and still-uncertain evidence base, and tirzepatide-specific data are noted as preliminary. Regard the alcohol association as the most substantiated of the behaviors discussed.
Journal of cardiovascular pharmacologyn=——Jul 28, 2026 - Study · SemaglutideMixed
Understanding Biased Signaling and Small-Molecule Binding for Treatment of Type 2 Diabetes Mellitus and Obesity at the Glucagon-Like Peptide-1 Receptor (GLP-1R) Based on Molecular Dynamics Simulations.
This is a molecular dynamics simulation study probing how semaglutide and tirzepatide, alongside small-molecule agonists, engage the GLP-1 receptor at the structural level. Its value is mechanistic insight into receptor binding and biased signaling to inform the design of orally available agonists, not any clinical or safety outcome. Readers should view it as basic pharmacology relevant to how these compounds work rather than how they perform in patients.
Medicinal chemistry researchn=—In vitroJul 27, 2026 - Study · SemaglutideMixed
The cost-effectiveness of second line diabetes medication added to standard therapy in preventing type 2 diabetes related nephropathy in Germany.
This is a Markov-microsimulation cost-effectiveness model, not a clinical trial; its outputs depend on published transition probabilities and cost inputs. It suggests semaglutide and tirzepatide are associated with modeled gains in kidney-related outcomes and survival, with semaglutide remaining cost-effective and tirzepatide constrained by its higher price. Readers should read the numbers as scenario estimates specific to the German statutory system rather than measured patient outcomes.
Cost effectiveness and resource allocationn=——Jul 27, 2026 - Study · SemaglutideMixed
Trends in publicly subsidized and private access to GLP-1 medicines indicated for type 2 diabetes in Australia, 2020-2025.
This population-level utilization study quantifies the sharp rise in semaglutide and tirzepatide use in Australia and highlights that a large share is accessed privately, outside subsidized care. It speaks to real-world demand, supply shortages, and equity of access rather than to efficacy or safety. The findings are descriptive and useful context for readers tracking market and access dynamics.
British journal of clinical pharmacologyn=—HumanJul 27, 2026 - Study · SemaglutideSupported
Nutritional intake changes during GLP-1 receptor agonist therapy: A systematic review and meta-analysis.
This systematic review and meta-analysis pools randomized and crossover trials to quantify how GLP-1 receptor agonists, including semaglutide and tirzepatide, affect measured food intake, finding a consistent reduction in acute energy intake with no heterogeneity in the primary analysis. The signal is robust for standardized meal tests but the authors caution that habitual, real-world intake is underreported and that adding an exploratory phase 1 trial introduced substantial heterogeneity. Read the results as strong evidence on short-term appetite suppression rather than long-term dietary behavior.
Diabetes & metabolic syndromen=—HumanJul 25, 2026 - Study · TirzepatideWeak / none
Tirzepatide-Induced Weight Loss and Exacerbation of Bipolar Disorder With Clozapine Treatment: A Case Report.
A single-patient case report describing weight loss on tirzepatide accompanied by a bipolar disorder exacerbation in the context of clozapine therapy. The possible interaction is noteworthy for clinicians, but a case report cannot separate the medication's role from the underlying illness course. No abstract was available to evaluate further detail.
Journal of clinical psychopharmacologyn=—HumanJul 24, 2026 - Study · TirzepatideSupported
Cardiovascular Outcomes of GLP-1-Based Medicines Among People With Overweight and Obesity: An Umbrella Review of Meta-Analyses of Randomized Controlled Trials.
An umbrella review synthesizing nine meta-analyses of GLP-1-based medicines and cardiovascular outcomes in overweight and obese populations, graded with GRADE. High-certainty evidence supported reduced MACE and myocardial infarction, but the benefit was driven by patients with established cardiovascular disease and lost significance in primary-prevention groups. Tirzepatide is the specifically tracked agent here, with signals of both cardiac benefit and increased heart rate that merit attention.
Obesity reviewsn=—HumanJul 22, 2026 - Study · SemaglutideSupported
Respiratory Adverse Events of Weight-Loss Drugs: A Systematic Review and Meta-Analysis.
A systematic review and meta-analysis of 123 studies assessing respiratory adverse events of weight-loss medications, including semaglutide and tirzepatide. The pooled randomized-trial data, judged at low risk of bias, showed no signal of increased respiratory harm versus placebo, though evidence specific to people with asthma was sparse. This is a reassuring, well-conducted synthesis on a focused safety question.
Annals of the American Thoracic Societyn=—HumanJul 21, 2026 - Study · SemaglutideMixed
GLP-1 Receptor Agonists as a Candidate Treatment for Opioid Use Disorder: From rats to humans.
A review spanning preclinical and clinical evidence on GLP-1 receptor agonists for opioid use disorder, covering semaglutide and tirzepatide among other agents. The animal data are relatively consistent, but human evidence rests on one small liraglutide trial plus observational database analyses, with dedicated semaglutide and tirzepatide trials still ongoing. The authors are appropriately cautious that confirmatory clinical trials are needed.
Biological psychiatryn=——Jul 21, 2026 - Study · SemaglutideSupported
Association between GLP-1 receptor agonists and alcohol-related hospitalisations among adults with alcohol use disorder: multi-target trial emulation study.
A large retrospective target-trial-emulation study using US electronic health records, reporting that initiation of semaglutide or tirzepatide was associated with lower rates of alcohol-related hospitalization across four emulated trials. The use of active comparators, propensity-score methods, and a negative-control outcome strengthens the analysis, but as an observational study it establishes association rather than causation and remains subject to residual confounding. The consistency of the effect across diabetes and obesity subgroups is notable.
BMJ openn=—HumanJul 21, 2026 - Study · TirzepatideSupported
Comparative Cardiovascular Outcomes of Tirzepatide and Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease.
This propensity-matched cohort is directly relevant to tirzepatide's cardiometabolic profile and reports consistent benefits across several outcomes. The signal is encouraging but observational, and the authors themselves call for prospective validation. Residual confounding and the one-year window are meaningful limits.
Journal of the American Heart Associationn=—HumanJul 17, 2026 - Study · TirzepatideWeak / none
Effect of short-term tirzepatide treatment on mean platelet volume in patients with obesity: a retrospective controlled study.
Tirzepatide is the direct subject, and the observed drop in mean platelet volume is a plausible inflammation-related signal. The authors appropriately frame the results as hypothesis-generating given the retrospective design, small size, short follow-up, and absence of direct platelet-function biomarkers. Not a basis for firm claims.
BMC endocrine disordersn=—HumanJul 16, 2026 - Study · TirzepatideWeak / none
Tirzepatide as a therapeutic tool for kidney impairment in obesity: insights from a real-world study.
Tirzepatide is the direct subject, and the reported improvement in estimated GFR is an interesting signal tied largely to weight loss. However, the sample is very small, uncontrolled, and only three months long, so the findings are preliminary. Kidney function was estimated, not directly measured.
Journal of translational medicinen=—HumanJul 16, 2026 - Study · SemaglutideWeak / none
Incretin-Based Therapies in Doxorubicin-Induced Cardiotoxicity: A Systematic Review of GLP-1 and Dual GIP/GLP-1 Agonists.
This review pools thirteen small rodent studies and reports incretin therapies were associated with better left ventricular function during doxorubicin exposure. Semaglutide and tirzepatide each appear in only a handful of animal studies, and the authors rate certainty as low-to-very-low. Findings are explicitly hypothesis-generating with no human data, so weight is limited.
Cardiovascular toxicologyn=——Jul 15, 2026 - Study · TirzepatideSupported
Real-world clinical outcomes of tirzepatide administration in older patients with type 2 diabetes, with a focus on the risk of hypoglycemia and weight loss-related parameters.
A secondary analysis of a real-world cohort with tirzepatide as the direct subject in an older population that trials often underrepresent. Reductions in HbA1c and body weight were associated with treatment, and no severe hypoglycemia was reported, though the authors stress that concomitant insulin and sulfonylurea doses were proactively lowered in many patients. As an observational study without a control arm, it describes real-world use rather than establishing comparative efficacy.
Endocrine journaln=—HumanJul 14, 2026 - Study · TirzepatideMixed
Effects of GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta-Analysis.
This meta-analysis of 41 RCTs reports GLP-1-based therapies are associated with a selective anti-inflammatory profile, with two tirzepatide trials specifically showing reduced IL-6. Tirzepatide is a tracked peptide but represents a small slice of the pooled data, and heterogeneity was moderate to high. Effects on IL-6 and TNF-alpha across the broader class were variable, warranting cautious interpretation.
Diabetes, obesity & metabolismn=—HumanJul 14, 2026 - Study · TirzepatideMixed
Incident Diabetic Retinopathy after Adjunctive Tirzepatide Treatment for 1 Year in Adults with Type 1 Diabetes.
This small retrospective cohort examined diabetic retinopathy incidence after a year of off-label tirzepatide in overweight type 1 diabetes patients. New retinopathy occurred at rates comparable to controls, with rapid HbA1c decline the more consistent risk factor. Tirzepatide is a genuine subject, but the sample is small and randomized trials are needed to confirm the safety signal.
Diabetes technology & therapeuticsn=—HumanJul 14, 2026 - Study · SemaglutideSupported
Cancer risk of glucagon-like peptide-1 receptor agonists for obesity: comparison with bariatric surgery and other weight-loss drugs.
This large TriNetX cohort compared semaglutide and tirzepatide users against bariatric surgery and other weight-loss drugs, finding therapeutic-dose use associated with lower colorectal and pancreatic cancer incidence and no increased cancer risk. Both tracked peptides are genuine subjects. As a retrospective, propensity-matched study it supports safety reassurance but cannot prove causation, and any-dose effects were not significant.
Journal of gastrointestinal surgeryn=—HumanJul 14, 2026 - Study · TirzepatideSupported
Medical Treatments for Obesity: What Does the Future Have in Store?
A systematic-search review of the obesity-pharmacotherapy landscape that positions tirzepatide among the highest-efficacy agents and looks ahead to multi-pathway drugs like retatrutide and CagriSema. As a narrative synthesis it aggregates trial findings rather than adding new data, and many named agents fall outside our tracked list. Useful for context and framing where the field is heading, with tirzepatide as the main tracked peptide.
The Journal of clinical endocrinology and metabolismn=——Jul 14, 2026 - Study · TirzepatideSupported
Tirzepatide, cardiovascular outcomes and mortality in obesity and diabetes: a systematic review and meta-analysis.
A well-powered meta-analysis of 22 randomized trials reporting an association between tirzepatide and reduced major adverse cardiovascular events (OR 0.87) and lower all-cause mortality, rated high certainty with low risk of bias. The composite benefit did not carry through to individual MACE components or heart failure hospitalizations, so the signal rests on the pooled endpoint. This is among the strongest evidence tiers we cover and is squarely about a tracked peptide.
Diabetes research and clinical practicen=—HumanJul 13, 2026 - Study · SemaglutideMixed
GLP-1 Receptor Agonists and Fertility: What Is Known So Far?
A narrative review of GLP-1 receptor agonists in fertility and PCOS care, where most of the reproductive-outcome evidence comes from liraglutide and exenatide rather than the peptides we track. Semaglutide and tirzepatide appear mainly around safety and washout guidance, and narrative reviews carry selection risk. The pregnancy-contraindication and washout points are the most durable takeaways for our readers.
JBRA assisted reproductionn=——Jul 13, 2026 - Study · TirzepatideMixed
Safety Profile of Tirzepatide in Real-World Clinical Practice: A Pharmacovigilance Study Using the FAERS Database.
This pharmacovigilance study mines the FAERS database for real-world tirzepatide safety signals and benchmarks them against semaglutide. Disproportionality analyses flag associations, not incidence or causation, so novel signals like starvation ketoacidosis are hypothesis-generating rather than confirmed. Useful safety context for readers, provided the reporting-bias caveat is kept front and center.
Diabetes, obesity & metabolismn=——Jul 13, 2026 - Study · TirzepatideMixed
Pharmacologic Treatment for Obstructive Sleep Apnea in Older Adults.
A narrative review of pharmacologic options for obstructive sleep apnea in older adults, within which GLP-1 receptor agonists and specifically tirzepatide are highlighted for improving hypoxic burden, apnea-hypopnea index, and sleep outcomes by reducing upper-airway adiposity. Tirzepatide is one of several agents surveyed rather than the paper's sole focus, and review-level summaries inherit the limits of the trials they cite. Useful orientation on an emerging tirzepatide indication, with modest standalone signal.
Drugs & agingn=——Jul 11, 2026 - Study · TirzepatideSupported
Tirzepatide compared with semaglutide in obesity disease: a subpopulation analysis applying Japan Society for the Study of Obesity criteria in the global SURMOUNT-5 trial.
A prespecified subpopulation analysis of the randomized SURMOUNT-5 trial, applying Japanese obesity criteria, found tirzepatide produced markedly greater weight loss than semaglutide (roughly 20% versus 13% at 72 weeks) with a comparable, mostly gastrointestinal safety profile. As a head-to-head RCT-derived comparison this carries real weight, though it is a subgroup of 383 and industry-sponsored, so the headline gap should be read as consistent with rather than independent confirmation of the main trial. Strong signal on relative efficacy for peptide readers.
Current medical research and opinionn=—HumanJul 11, 2026 - Study · TirzepatideSupported
Lower fall and femoral fracture risks with semaglutide and tirzepatide compared with DPP-4 inhibitors in older adults with type 2 diabetes.
A large retrospective cohort using TriNetX and propensity-score matching found semaglutide and tirzepatide associated with roughly halved femoral fracture risk and about a third lower fall risk versus DPP-4 inhibitors in older adults with type 2 diabetes. The effect sizes are consistent across both drugs and several subgroups, which strengthens the signal, but this is observational and residual confounding remains possible. Solid hypothesis-generating evidence for a musculoskeletal benefit beyond glucose control, not proof of causation.
Osteoporosis internationaln=—HumanJul 11, 2026 - Study · TirzepatideWeak / none
Influence without medical expertise: a social network analysis of Mounjaro discussions on twitter (X).
This is a social-media discourse study, not clinical research: an observational social-network and sentiment analysis of 5,566 tweets about Mounjaro (tirzepatide) collected over roughly six weeks in early 2025. It is genuinely about a tracked peptide, but it measures conversation, not the drug's effects. The findings are sociologically useful and squarely on-brand for a property covering community synthesis: the most influential voices were non-medical — public figures and patients sharing personal experiences — sentiment ran positive (62.6% favorable), and discussion clustered around weight loss, brand comparisons (Ozempic, Wegovy), and diabetes. The authors' own point is the important one: non-experts dominate online tirzepatide discourse, underscoring the need for evidence-based communication. Caveats: a single platform, a short window, automated sentiment tools that miss nuance and sarcasm, and no clinical outcomes at all. Read this as a snapshot of the information environment around tirzepatide, not as evidence about the medication itself.
Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Societyn=——Jul 10, 2026 - Study · TirzepatideWeak / none
Tirzepatide and risk of newly diagnosed aortic stenosis in patients with obesity: a multi-institutional real-world cohort study.
This large real-world cohort is directly about tirzepatide and asks a novel question: whether the dual GIP/GLP-1 agonist is associated with fewer new diagnoses of aortic stenosis. Using a global federated database with an active-comparator, new-user design and 1:1 propensity matching (584,236 patients), researchers found tirzepatide users had a lower risk of the AS-or-aortic-valve-replacement composite than other GLP-1 RA users (0.2% vs 0.6%; HR 0.90), plus lower all-cause mortality. The design is methodologically careful — a negative-control outcome (skin cancer) showed no association, and E-values were reported — which strengthens plausibility. But the caveats are decisive and the authors state them plainly: this is observational and hypothesis-generating; absolute event rates are tiny; aortic stenosis is often silent for years so ascertainment is incomplete; no echocardiographic progression data exist; and the mortality signal is vulnerable to healthy-user bias. Read this as an intriguing hypothesis about tirzepatide and valve disease, not as evidence of a preventive effect. Prospective confirmation is needed.
BMC cardiovascular disordersn=—HumanJul 9, 2026 - Study · TirzepatideMixed
Special Considerations When Using GLP-1 Receptor Agonists in the Treatment of Obesity and Diabetes Mellitus Type 2 in Older Adults.
This is a narrative review on using GLP-1 receptor agonists — semaglutide and tirzepatide named among them — in older adults with obesity or type 2 diabetes. As a review it synthesizes rather than generates evidence, so its role for readers is orientation, not new data. Its most useful contribution is framing the trade-offs specific to older patients: the authors flag sarcopenia (age-related muscle loss) as a real concern when pursuing weight loss in this group, alongside polypharmacy and cumulative side-effect burden. They note that while large trials support these drugs for lowering HbA1c and body weight and for renal and cardiovascular benefit, direct evidence in older adults specifically remains limited. That gap is the honest headline. Both tracked peptides appear, but only as class exemplars — the review does not isolate their individual geriatric profiles. Weight this as a balanced clinician-facing overview of cautions, not as a peptide-specific evidence update.
Advances in therapyn=——Jul 9, 2026 - Study · TirzepatideMixed
Patterns of Use for GLP-1 Receptor Agonists in a Weight Management Cohort: A Military Health System Database Analysis of Active Duty Service Members From 2021 to 2025.
This retrospective cohort tracks how long people actually stay on weight-management injectables — a real-world adherence question that matters as much as trial efficacy. Among 10,649 active-duty service members starting liraglutide (Saxenda), semaglutide (Wegovy), or tirzepatide (Zepbound) between 2021 and 2025, tirzepatide showed the highest one-year persistence (81.9%) and adherence, semaglutide was intermediate (70.7%), and liraglutide trailed badly (34.2%). Adjusted models put tirzepatide's discontinuation hazard 33% below semaglutide's. Both tracked peptides are central here. Caveats: this is observational, so persistence differences may reflect dosing schedule (weekly vs daily), supply and formulary dynamics, tolerability, and patient selection rather than any intrinsic superiority — and the cohort is a specific, relatively young and health-screened military population, which limits generalizability. It measures whether people keep taking the drug, not how much weight they lost. Read it as useful real-world adherence signal favoring the weekly agents, not as comparative efficacy evidence.
Military medicinen=—HumanJul 9, 2026 - Study · TirzepatideWeak / none
Association of Glucagon-Like Peptide-1 Receptor Agonists With Menstrual Events in Reproductive-Aged Patients.
This pharmacovigilance analysis is directly about both tracked peptides. Using FDA adverse-event reports through March 2026, researchers ran disproportionality and Bayesian analyses in women aged 12–55 and found that semaglutide had the broadest signal — disproportionate reporting of heavy menstrual bleeding, intermenstrual bleeding, clots, oligomenorrhea, and anovulatory cycles — while tirzepatide showed narrower signals (intermenstrual bleeding, clots) and liraglutide showed none. The critical caveat is the data source: FAERS is a spontaneous-reporting system, so it can flag a possible association but cannot establish incidence, causation, or whether the drug or the underlying weight/metabolic change drives the pattern. Reporting is subject to notoriety and stimulated-reporting bias — heavily publicized drugs generate more reports. So this is a signal-generation study, not confirmatory. Its practical value is that it supports raising menstrual health in counseling for reproductive-aged patients on these agents. Weight it as a hypothesis worth prospective study, not as established risk.
Obstetrics and gynecologyn=—HumanJul 9, 2026 - Study · RetatrutideSupported
Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.
This is a major, GRADE-rated network meta-analysis — 262 RCTs, 99,791 participants, 19 drugs — and it puts both tracked peptides at the center of the obesity-pharmacotherapy map. With moderate-to-high certainty, tirzepatide showed the largest one-year weight loss (−14.9% vs lifestyle), with subcutaneous and oral semaglutide also substantial (−9.8% and −10.9%). Crucially, subcutaneous semaglutide was the only drug associated with reduced all-cause mortality and myocardial infarction, and both semaglutide and tirzepatide were associated with lower heart-failure risk — though the mortality/MI estimates are driven by cardiovascular-outcome trials in high-risk populations, an important scoping caveat. The analysis is admirably balanced on harms: larger weight loss generally came with more discontinuation and gastrointestinal events, and tirzepatide, while cutting fat mass most (−25.7%), also cut lean mass most (−8.3%) — a real signal on muscle loss. No drug meaningfully improved quality of life. This is high-quality synthesis and among the most useful single references for weighting these peptides. Read the benefit and harm columns together.
BMJ (Clinical research ed.)n=—HumanJul 8, 2026 - Study · TirzepatideSupported
Neuropsychiatric Outcomes With Tirzepatide, Semaglutide, and Other GLP-1 Receptor Agonists.
This large real-world cohort speaks directly to a well-publicized worry: whether semaglutide and tirzepatide carry neuropsychiatric risk, including depression and suicidal ideation. Drawing on a federated network of over 192 million patients with propensity-matched, new-user designs (85,546 pairs for tirzepatide vs semaglutide; 80,115 for semaglutide vs other GLP-1 RAs), researchers found the two tracked peptides had comparable psychiatric risk over two years, with only a small, cautiously-flagged Year-2 anxiety signal for tirzepatide. Semaglutide was associated with lower rates of depression, anxiety, and suicidal ideation than earlier-generation GLP-1 RAs. Both peptides are central. The caveats are real: this is observational, so residual confounding by indication and channeling (who gets prescribed what) can bias comparisons; coded diagnoses undercount psychiatric events; and the tirzepatide-vs-other-GLP-1 comparison isn't shown. Reassuring as a signal against a heightened neuropsychiatric hazard, but not a substitute for randomized safety adjudication. Weight it as supportive real-world evidence, appropriately hedged.
Diabetes, obesity & metabolismn=—HumanJul 8, 2026 - Study · TirzepatideSupported
Effects of Tirzepatide in Obesity-Related HFpEF by Sex: A Prespecified Secondary Analysis From the SUMMIT Trial.
This is a prespecified secondary analysis of the SUMMIT randomized trial (731 patients, tirzepatide vs placebo), examining whether the drug's benefit in obesity-related heart failure with preserved ejection fraction (HFpEF) differs by sex. Tirzepatide is the trial intervention, so relevance is high, and the source is a randomized design — the strongest study type here. Researchers found that women entered sicker (higher BMI, worse symptoms, poorer walk distance) while men had more cardiac remodeling and paracardiac fat, yet tirzepatide's effect on the composite of cardiovascular death or worsening heart failure was consistent across sexes (HR 0.66 in women, 0.61 in men; interaction P=0.81), as were gains in symptom scores and walk distance. One nuance: weight loss tracked more tightly with symptom improvement in women. Caveats: this is a secondary, subgroup-focused analysis of a single trial with a modest sample, so it is not powered as definitive sex-specific evidence, and prespecification tempers but does not eliminate multiple-comparison concerns. Read it as reassuring evidence that tirzepatide's HFpEF benefit holds across sexes.
JACC. Heart failuren=—HumanJul 7, 2026 - Study · TirzepatideSupported
Changes in patient-reported outcomes and objective assessments based on baseline symptom severity in SURMOUNT-OSA: Post-hoc analyses.
These are post-hoc analyses of SURMOUNT-OSA, the two 52-week randomized placebo-controlled trials of tirzepatide in adults with moderate-to-severe obstructive sleep apnea and obesity — directly tirzepatide-specific and drawn from a robust trial program. The new slice here asks whether patients with worse baseline symptoms improved more. The pattern reported: tirzepatide-treated participants who started out more fatigued, sleepier, or with poorer sleep quality tended to show larger gains on the corresponding patient-reported measures, while objective measures (apnea-hypopnea index, weight, sleep-apnea remission) improved similarly across subgroups. The important interpretive caveat is that these are post-hoc, subgroup analyses — hypothesis-generating by nature, prone to regression-to-the-mean (those with worse baseline scores have more room to improve), and not the trial's pre-specified primary endpoints. So the headline signal that tirzepatide consistently outperformed placebo is well-grounded in the parent RCT, while the 'worse-off improve more' subgroup nuance should be read as exploratory.
Sleepn=—HumanJul 7, 2026 - Study · TirzepatideContradicted
Preventative semaglutide and tirzepatide treatment does not alter disease progression in the 5xFAD mouse model of Alzheimer's disease.
This is a directly peptide-specific preclinical study, and notably a negative one — worth surfacing precisely because the field's momentum runs the other way. Working in the 5xFAD mouse model of Alzheimer's, researchers tested semaglutide (a GLP-1 receptor agonist) and tirzepatide (a GLP-1/GIP co-agonist) as preventive treatments. Both did what these peptides reliably do — lowered body weight and improved glucose tolerance — but the authors report no measurable effect on memory or learning tasks, amyloid-beta plaque burden, or glial activation, even when treatment began before overt pathology and continued for months. A companion inflammation challenge showed no change in microglial activation. These are preclinical findings in a genetically engineered mouse model; human data would be needed before any clinical conclusion. Still, the result is a useful counterweight to enthusiasm about incretin therapies as Alzheimer's disease-modifiers, and it comes from a well-designed, temporally staged experiment.
Cell reports. Medicinen=—AnimalJul 7, 2026 - Study · TirzepatideWeak / none
Potential role of tirzepatide, a dual GLP-1 and GIP receptor agonist, for preventive treatment of migraine: A case series.
This case series reports two patients with migraine whose headache frequency fell after starting tirzepatide, a dual GLP-1/GIP receptor agonist. The authors are appropriately cautious: both patients also lost weight, a well-known migraine modifier, which they flag as a major confounder limiting any migraine-specific interpretation, and they frame the observations as preliminary. Two uncontrolled cases are the weakest evidence tier, no comparison, no blinding, causation not established. Interest in GLP-1-based agents for headache stems partly from work on idiopathic intracranial hypertension, but a role in migraine is not established. Read this as a hypothesis worth formal study, not as evidence that tirzepatide reduces migraine frequency; controlled trials measuring headache outcomes would be required before any conclusion.
Headachen=—HumanJul 6, 2026 - Study · TirzepatideWeak / none
Real-World Effectiveness and Safety of Tirzepatide in Type 1 Diabetes and Obesity: Impact on Glycaemia, Weight, and Cardiometabolic Risk Markers.
This retrospective cohort compared 142 adults with type 1 diabetes and obesity started on tirzepatide against 50 matched controls over 12 months, notable because tirzepatide is not indicated in type 1 diabetes. Researchers reported significant reductions versus controls in HbA1c (-6.5 mmol/mol, about 0.6%), weight (-13.4 kg) and total daily insulin (-29.9 units), plus improvements in blood pressure and lipids, with 89.4% still on treatment at one year and no between-group difference in severe hypoglycaemia, ketoacidosis or hospitalisation. As a single, modest-sized, retrospective observational study it cannot exclude confounding, and ketoacidosis risk in type 1 diabetes warrants ongoing caution despite the reassuring signal here. The authors rightly call for randomised trials. Read it as promising real-world, hypothesis-generating data in an off-label, high-risk population, not established practice.
Diabetes, obesity & metabolismn=—HumanJul 6, 2026 - Study · TirzepatideMixed
Cardiovascular Outcomes With Tirzepatide Versus GLP-1 Receptor Agonists in Overweight or Obesity: A Systematic Review and Meta-Analysis.
This systematic review and meta-analysis (eight studies, one randomised and seven observational, 323,439 patients) compared tirzepatide with GLP-1 receptor agonists for cardiovascular outcomes in adults with overweight or obesity. Researchers reported that tirzepatide was not associated with a statistically significant reduction in major adverse cardiovascular events versus GLP-1 RAs (HR 0.85, 95% CI 0.70-1.04), with very high heterogeneity (I-squared 90.4%). Estimates leaned in tirzepatide's favour for all-cause and cardiovascular mortality but crossed or touched the line of no difference. The evidence base is dominated by observational studies, so confounding limits causal reading, and the wide heterogeneity signals the studies are not measuring the same thing. The honest takeaway: no confirmed cardiovascular advantage over GLP-1 RAs yet; dedicated randomised outcome trials are needed.
Diabetes, obesity & metabolismn=—HumanJul 6, 2026 - Study · TirzepatideSupported
Time to benefit of incretin-based therapies in adiposity-related heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis.
This meta-analysis reconstructed individual-participant data from four randomised trials (4,149 adults with overweight or obesity and heart failure with mildly reduced or preserved ejection fraction) to estimate how quickly incretin-based therapies, specifically semaglutide and tirzepatide, separate from placebo. Researchers reported a reduction in worsening heart-failure or cardiovascular-death events (hazard ratio 0.59) with low risk of bias and moderate-to-high certainty by GRADE, and a nominal time to first statistical significance of about four months, sustained from roughly six months onward. Because this pools two distinct agents in a specific obesity-related HFpEF/HFmrEF population, the finding should be read at the class level rather than as agent-specific evidence, and the reconstructed-IPD method carries assumptions. Still, the consistency and event reduction make this among the stronger signals for semaglutide and tirzepatide in this cardiac population.
Journal of cardiac failuren=—HumanJul 4, 2026 - Study · TirzepatideWeak / none
Current Concepts in Perioperative Guidance and Outcomes in Hand Surgery Patients Taking Glucagon-Like Peptide-1 Receptor Agonists.
This is a narrative concepts review for hand surgeons on managing patients taking GLP-1 receptor agonists, naming semaglutide and tirzepatide specifically. The clinical hinge is delayed gastric emptying and the theoretical aspiration risk around anesthesia, which has driven evolving perioperative guidance. The authors report that the existing hand and orthopedic literature is limited, but that multiple studies to date describe no notable increase in postoperative complications, and they raise open questions about bone and wound healing during rapid weight loss and anesthesia-related risk. As a narrative review it pools no data and grades no evidence; its value is orientation and unresolved-question framing rather than a quantified risk estimate. Useful context on how these peptides intersect with surgical care, appropriately hedged.
The Journal of hand surgeryn=——Jul 3, 2026 - Study · TirzepatideMixed
Outpatient Dispensing Patterns and Changes in Tirzepatide Strength Mix in Japan: A Study Using the National Open Claims Data.
This is a pharmacoepidemiologic description of dispensing and product-strength trends, not a study of clinical effect. It is useful market-context evidence about tirzepatide uptake in Japan but says nothing about efficacy, safety, or individual outcomes.
Cureusn=——Jul 1, 2026 - Study · TirzepatideWeak / none
A Case of Severe Hypercalcemia in a Patient Taking Tirzepatide: Potential Risk Factors.
A single-patient case report raising a possible association between tirzepatide and severe hypercalcemia in the setting of multiple contributing factors, including a thiazide, calcium and vitamin D supplements, and kidney disease. A case report cannot establish causation, and the concurrent medications and comorbidities complicate attribution. Readers can read this as a signal for calcium monitoring in similar high-risk scenarios rather than evidence of a general tirzepatide effect.
Cureusn=—HumanJul 1, 2026 - Study · TirzepatideWeak / none
Hypersensitivity Reaction to Tirzepatide With Demonstrated Tolerance to Semaglutide: A Case Report.
A single case report describing tirzepatide-specific hypersensitivity in a 25-year-old woman who later tolerated semaglutide after supervised testing. As an individual case, it cannot establish how common such reactions are, but it illustrates that hypersensitivity to one GLP-1-based agent does not necessarily extend to others in the class. The main value is in documenting a diagnostic approach using intradermal testing and supervised challenge.
Clinical case reportsn=—HumanJul 1, 2026 - Study · TirzepatideSupported
Approved weight loss drugs for obesity with a thorough emphasis on GLP-1 agonist medications: A systematic review.
A PRISMA-based systematic review of 15 studies on approved anti-obesity pharmacotherapies, with a focus on GLP-1 and dual incretin agents. For tracked peptides it reports dose-dependent weight loss, semaglutide 2.4 mg around -15%, tirzepatide roughly -15% to -18.5%, alongside glycemic and cardiometabolic improvements (HbA1c, blood pressure, LDL) and predominantly mild gastrointestinal adverse events, with serious events, pancreatitis and gallbladder complications described as rare and discontinuation generally under 15%. As a qualitative systematic review it synthesizes rather than pools data, so it lacks the quantitative rigor of a meta-analysis, and the 15-study base spans heterogeneous populations. The findings are consistent with the broader trial record for semaglutide and tirzepatide. Read as a solid orienting summary of where these agents stand on weight and cardiometabolic measures, with the usual caveat that review-level synthesis is only as strong as its included studies.
Disease-a-month : DMn=——Jul 1, 2026 - Study · TirzepatideWeak / none
Glucagon-Like Peptide-1 Receptor Agonists: Their Therapeutic Potential in Cystic Fibrosis.
A narrative review of GLP-1 receptor agonists in cystic fibrosis and CF-related diabetes, where the authors note the evidence base is almost entirely case reports and case series. Reported observations include improved HbA1c and glucose-monitoring metrics, weight reduction (notably in patients on CFTR modulator therapy), and even improved lung function, with tirzepatide specifically noted to have yielded favorable outcomes; a preliminary bone-resorption signal is also raised. This is a hypothesis-rich but evidence-thin area: findings rest on anecdotal reports, results have been discordant, and the authors flag real risks, pancreatitis, nausea/vomiting, nutritional depletion, bowel dysmotility and distal intestinal obstruction syndrome, that matter especially in a population prone to malnutrition. Weight this as early, exploratory signal for tirzepatide in CF, explicitly not established, with the authors calling for large prospective multicenter trials before clinical implications can be drawn.
Advances in therapyn=——Jul 1, 2026 - Study · TirzepatideWeak / none
Six-Month Real-World Effectiveness, Persistence and Safety of Low-to-Moderate Dose Tirzepatide in Adults With Obesity: A Multicentre Observational Study.
A multicenter retrospective observational study across 15 Greek endocrinology clinics following 260 adults with obesity who started low-to-moderate-dose tirzepatide; 208 (80%) completed six months. Median weight loss was substantial, 94.2% achieved >=5%, 77.9% >=10%, 47.1% >=15%, and about 20% >=20%, with weight loss independent of baseline BMI and greater in women. Discontinuation was 20%, most often during titration and frequently for goal achievement or cost; gastrointestinal events rarely stopped treatment. As real-world data this usefully complements trials by showing persistence and outcomes in routine practice. The caveats are design-based: single-arm, retrospective, no control group, and six months only, so it cannot isolate the drug's effect from concurrent care or speak to durability. The results are consistent with tirzepatide's established weight effects. Read as supportive real-world corroboration, not independent confirmation.
Diabetes, obesity & metabolismn=—HumanJul 1, 2026 - Study · TirzepatideMixed
Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity.
An indirect comparison using multilevel network meta-regression to weigh injectable tirzepatide against daily oral semaglutide 50 mg for weight management, anchoring on the SURMOUNT-1 and OASIS 1 trials and adjusting for population differences. Tirzepatide 10 and 15 mg were associated with statistically greater weight and waist-circumference reductions and higher odds of hitting >=5–20% weight-loss thresholds than oral semaglutide, with cardiometabolic and safety profiles described as improved or comparable. The ranking is consistent with the broader record on these two agents. The central caveat is in the method: this is an indirect, cross-trial comparison, not a head-to-head trial; the two pivotal studies differed in design and duration, and adjustment can reduce but not remove that mismatch. Read as a reasonable model-based estimate favoring higher-dose tirzepatide on weight, pending direct comparative data, which does not yet exist.
Diabetes, obesity & metabolismn=—HumanJul 1, 2026 - Study · TirzepatideWeak / none
Clinical Characteristics of Users of Weight Loss Drugs: Population-Based Case-Control Study.
A nationwide Norwegian nested case-control study describing who starts weight-loss drugs, using dispensing and diagnosis registries; each user was matched to five population controls. Among agents, semaglutide (Wegovy) dominated by volume (150,036 initiators) with tirzepatide far smaller (3,596). Users carried heavier comorbidity burdens than controls, more hypertension, hyperlipidemia, sleep apnea, back pain, and more antidepressant and opioid use. This is descriptive epidemiology, not an efficacy or safety study: it characterizes the treated population and prescribing patterns, not outcomes. Its editorial value is market-and-access intelligence, showing real-world uptake skewed toward semaglutide and toward patients with complex needs, plus an equity note on education level. Caveats: registry data reflect what is dispensed and coded, not why, and the design cannot speak to how well any drug works. A useful population snapshot, weak as clinical evidence.
Diabetes, obesity & metabolismn=——Jul 1, 2026 - Study · TirzepatideMixed
Pre-Pregnancy GLP-1 Receptor Agonist or Tirzepatide Use and Gestational Diabetes Risk: Evaluating Pharmacodynamic Carry-Over Versus Post-Discontinuation Metabolic Rebound in a Multinational Federated Cohort.
A retrospective TriNetX cohort examining whether GLP-1 receptor agonist or tirzepatide use before pregnancy relates to gestational diabetes risk. With BMI-matched comparison, preconception use followed by discontinuation more than 90 days before pregnancy carried a gestational-diabetes risk similar to non-users, despite a modest post-stopping weight rebound. Abrupt discontinuation within 90 days of conception was associated with a 53% higher risk, which the authors attribute to a steeper weight rebound rather than the prior drug exposure itself. The nuance is the finding: timing and speed of weight regain after stopping, not the exposure per se, tracked with risk. Caveats are substantial, observational design, the drugs are pooled (tirzepatide with GLP-1 RAs, not isolated), modest event counts, and reliance on federated records. The authors call for prospective confirmation. Read as a hypothesis about the post-withdrawal window, not established guidance.
Diabetes, obesity & metabolismn=—HumanJul 1, 2026 - Study · TirzepatideWeak / none
Incretin-Based Anti-obesity Medications in Polycystic Ovary Syndrome: The Evidence Map.
A narrative, drug-by-drug 'evidence map' of incretin anti-obesity medications in polycystic ovary syndrome. The key takeaways for tracked peptides: semaglutide has sparse but mechanistically interesting PCOS data with early signals around weight and conception, while tirzepatide has no PCOS-specific evidence at all; the authors are explicit that its use here rests only on extrapolation from obesity and diabetes trials and should not be extended to PCOS on that basis. Liraglutide (not tracked) has the densest evidence. As a narrative review this maps gaps rather than generating data, and the authors stress that reproductive, pregnancy-safety, adolescent and long-term outcomes remain major unknowns. Editorially valuable precisely for calibrating expectations: it documents how thin the peptide-specific PCOS evidence is. Read as an honest gap analysis, not support for use in PCOS.
Drugsn=——Jul 1, 2026 - Study · TirzepatideWeak / none
Glucagon-Like Peptide-1 Receptor Agonist and Hyponatremia: A Potential Association.
A single case report describing recurrent low blood sodium (hyponatremia) in a 73-year-old woman on long-term chlorthalidone (a thiazide-like diuretic) after starting tirzepatide, with sodium levels tracking dose changes, normalizing at lower doses and recurring symptomatically at 10 mg weekly, then resolving when tirzepatide was stopped. The authors frame this as a temporal association possibly amplified by the concurrent diuretic. As a case report this is the weakest evidence tier and cannot establish frequency or causation; the dose-response pattern within one patient is suggestive but could reflect the diuretic, fluid intake changes from nausea, or other factors. Editorially it is a useful co-prescribing caution: it flags that clinicians may consider monitoring sodium when GLP-1-type agents are combined with sodium-affecting drugs. Read as an isolated, mechanism-plausible signal, not a quantified risk.
JACC. Case reportsn=—HumanJul 1, 2026 - Study · CagrilintideSupported
Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials.
A network meta-analysis pooling 25 randomized trials and 12 interventions to compare advanced anti-obesity agents. Tirzepatide 15 mg produced the greatest percent weight reduction (mean difference -17.97%), with CagriSema close behind (-17.84%) and semaglutide 7.2 mg at -14.66%; at the >=20% weight-loss threshold CagriSema and tirzepatide 15 mg led. Gastrointestinal adverse events rose with all treatments, while serious adverse events were comparable to placebo. As a meta-analysis of RCTs this sits near the top of the evidence hierarchy, and the ranking of tirzepatide and semaglutide is consistent with the broader trial record. The main caveats are inherent to network meta-analysis: it mixes indirect comparisons across trials with differing populations and durations, so the precise numeric ordering (especially tirzepatide vs CagriSema) carries uncertainty. The authors note no direct head-to-head data exist and call for them. Strong, well-grounded synthesis.
Endocrinology, diabetes & metabolismn=—HumanJul 1, 2026 - Study · TirzepatideWeak / none
Effects of Tirzepatide on Metabolic Parameters in Patients with Psoriasis and Obesity: 24-Week Real-World Study.
A prospective observational study of 64 adults with chronic plaque psoriasis and obesity given low-dose tirzepatide (2.5 titrated to 5 mg weekly) while maintained on stable ixekizumab. At 24 weeks the study reported about 10% weight loss and significant improvements in fasting glucose, LDL, triglycerides and liver enzymes, plus a 76% drop in PASI score. The metabolic changes are consistent with tirzepatide's established weight effects. The psoriasis-severity result needs a heavy caveat: patients stayed on an active biologic (ixekizumab), so the PASI improvement cannot be attributed to tirzepatide, and there is no control arm. This is a single-arm, uncontrolled cohort, useful for showing metabolic parameters moved in a psoriasis population, but not for isolating a skin benefit. Read the metabolic signal as supportive and the skin-severity figure as confounded and hypothesis-level at best.
Dermatology and therapyn=—HumanJul 1, 2026 - Study · TirzepatideWeak / none
Tirzepatide for weight and behavior management in a patient with Smith-Magenis syndrome.
A single case report of a 31-year-old woman with Smith-Magenis syndrome, a rare neurodevelopmental disorder with hyperphagia-driven obesity, given tirzepatide titrated to 5 mg weekly. Over 10 months she lost 9.4% of her body weight (7.3 kg) with improved fasting glucose, and caregivers reported reduced food-seeking, less impulsivity and a measured reduction in aggression; the drug was described as well tolerated. This is a single patient, the weakest evidence tier, and the behavioral observations are caregiver-reported and open-label, highly susceptible to expectation effects. The metabolic changes are consistent with tirzepatide's known weight effects; the behavioral claims are intriguing but should be read as anecdote generating a hypothesis about central appetite and behavior pathways, not evidence of a neuropsychiatric benefit. Useful mainly as a first description in an ultra-rare population where no prior data existed.
JCEM case reportsn=—HumanJul 1, 2026 - Study · TirzepatideWeak / none
Tirzepatide for Recurrent Weight Gain after Bariatric Procedures: Real-World Evidence of Efficacy and Safety.
A small observational cohort (34 patients) testing tirzepatide in people who regained weight after bariatric surgery or endoscopic therapy. Over 24 weeks on weekly tirzepatide (2.5–10 mg), mean total body weight loss was 18.1% with reduced waist circumference; adverse events were gastrointestinal (constipation, diarrhea, nausea), described as generally mild and not leading to discontinuation. The finding is encouraging for a real clinical gap, but the design is the main caveat: no control group, a single arm, only 34 patients, and just 24 weeks. Without a comparator we cannot separate the drug's effect from expectation or concurrent behavior change, and durability beyond six months is unknown. The authors frame it as preliminary. Weight this as a hypothesis-supporting pilot signal in a specific post-surgical population, consistent with tirzepatide's broader weight-loss data but far from confirmatory on its own.
Obesity surgeryn=—HumanJul 1, 2026 - Study · TirzepatideMixed
Dulaglutide in the era of tirzepatide and semaglutide: reaffirming its role in contemporary cardiometabolic care.
A narrative review arguing that dulaglutide retains a place alongside newer agents. For our tracked peptides, the useful content is comparative: the authors note that tirzepatide and semaglutide deliver larger reductions in HbA1c and body weight than dulaglutide, while framing dulaglutide's distinct strength as its cardiovascular outcome data (REWIND) and accessibility. They cite SURPASS-CVOT, which established tirzepatide's non-inferiority to dulaglutide for cardiovascular outcomes. As a narrative review this is synthesis and argument, not new data, and it is explicitly written to defend dulaglutide's role, so read the framing with that intent in mind. It is a reasonable orientation to where tirzepatide and semaglutide sit on efficacy versus an older comparator, but it should not be read as a systematic or quantitative comparison. Weight it as context, not evidence.
Diabetology internationaln=——Jul 1, 2026 - Study · TirzepatideWeak / none
Starvation-Type Euglycemic Ketoacidosis After Unsupervised Tirzepatide Use in a Non-Obese, Non-Diabetic Woman.
A single case report describing a 30-year-old woman without diabetes or obesity (BMI 24.8) who developed euglycemic ketoacidosis after self-administering tirzepatide obtained without a prescription for weight loss, then raising her own dose. She presented with days of severe vomiting and poor intake; labs showed high-anion-gap metabolic acidosis with near-normal glucose and elevated ketones. Symptoms resolved within 36 hours after stopping the drug and receiving dextrose, fluids and supportive care. As a case report this is the weakest tier of evidence and cannot establish how often this happens. Its editorial value is the context: this is a documented harm tied to unsupervised, non-prescribed use outside the drug's approved population. The authors describe the mechanism as starvation ketosis driven by appetite suppression and vomiting, not diabetic ketoacidosis. A useful cautionary data point about self-sourced use.
The American journal of case reportsn=—HumanJul 1, 2026 - Study · TirzepatideMixed
Association of Tirzepatide versus Glucagon-Like Peptide-1 Receptor Agonists with Incident Glaucoma in Patients with Type 2 Diabetes: A Retrospective Cohort Study.
In this retrospective cohort of 51,540 adults aged 60+ with type 2 diabetes drawn from a multinational database, tirzepatide was associated with a lower two-year risk of primary open-angle glaucoma than GLP-1 receptor agonists (hazard ratio 0.65, 95% CI 0.44–0.96). Groups were 1:1 propensity-matched, and the signal held across several sensitivity analyses. This is observational data: propensity matching cannot rule out residual confounding (for example, differences in who gets prescribed tirzepatide), and the wide confidence interval nudges close to 1.0. The absolute event numbers are modest, and the comparison is tirzepatide versus another active drug class, not versus placebo. The authors themselves call for further study to confirm clinical significance. Read this as a hypothesis-generating, safety-adjacent signal, not evidence that tirzepatide changes glaucoma risk.
Ophthalmology sciencen=—HumanJul 1, 2026 - Study · TirzepatideMixed
Tirzepatide as a multi-organ integrator in metabolic diseases: a review of molecular mechanisms and clinical translation.
This is a narrative review synthesizing tirzepatide's mechanisms across organ systems — pancreatic beta-cells, fat tissue, liver, gut, cardiovascular system, kidneys, brain and gut microbiota — framing the dual GIP/GLP-1 agonist as a 'multi-organ integrator.' It draws on clinical trials (the SURPASS and SURMOUNT programs), preclinical work and prior reviews, describing improved glucose control and weight loss versus comparators, better lipids and reduced hepatic steatosis, plus preclinical microbiome and intestinal-barrier effects. As a narrative review it neither pools data nor grades evidence, and it mixes established clinical-trial findings with preclinical mechanistic claims; readers should keep those tiers distinct — the microbiome and gut-barrier signals are preclinical, while the weight and glycemic benefits rest on large trials. A useful mechanistic and clinical overview of tirzepatide, appropriately hedged by the authors' own note that broader applications need confirmation in real-world and longer-term study.
Endocrinen=——Jul 1, 2026 - Study · TirzepatideMixed
Tirzepatide Is Associated With Improved Metabolic Outcomes in People With Type 1 Diabetes and Overweight or Obesity: A Retrospective Cohort Study.
This is a small retrospective matched cohort (23 tirzepatide users vs 23 controls, two Sydney centers) examining tirzepatide as an off-label adjunct in adults with type 1 diabetes and overweight or obesity — a population outside its usual type 2/obesity indication. Over roughly 28–31 weeks, researchers reported that tirzepatide was associated with markedly greater weight loss (about 10% vs essentially none) and a substantial reduction in total daily insulin, along with improvements in a glucose-control index, glucose variability and carbohydrate intake; blood pressure, lipids, and kidney and liver measures did not differ. The effect sizes are meaningful but the caveats are large: only 23 treated patients, retrospective non-randomized design despite matching, short follow-up, and — importantly in type 1 diabetes — safety questions (including hypoglycemia and ketoacidosis risk with insulin reduction) that this study is not powered to assess. Read as a preliminary, hypothesis-generating signal; the authors rightly call for larger prospective trials.
Diabetes, obesity & metabolismn=—HumanJul 1, 2026 - Study · TirzepatideMixed
Weight loss and cardiovascular outcomes with incretin-based therapies after metabolic and bariatric surgery: a nationwide US cohort study.
This is a large nationwide retrospective cohort (208,155 post-bariatric-surgery patients, 39,750 on incretin therapy) examining semaglutide and tirzepatide as add-on treatment after metabolic and bariatric surgery. Among those on therapy at least a year, tirzepatide was associated with greater additional weight loss than semaglutide (17.2% vs 12.0% total weight loss; adjusted difference ~5.2 points) in a dose-dependent way, and later post-surgical initiation was associated with more weight loss than earlier. Notably, in matched landmark analyses, pooled incretin therapy was not associated with a reduction in major adverse cardiovascular events (HR 0.91, CI 0.80–1.05) — a null result the authors present honestly. Standard observational caveats apply: confounding by indication, adherence, and the fact that patients starting later may differ systematically. The authors explicitly call for prospective work to establish causality and cardiovascular benefit. Solid comparative signal on weight, appropriately cautious on hard outcomes.
EClinicalMedicinen=—HumanJul 1, 2026 - Study · TirzepatideMixed
Real-World Comparative Effectiveness of Tirzepatide and Semaglutide for Obesity: A Multicentered Study.
This is a retrospective, multicenter real-world cohort (511 US adults) directly comparing tirzepatide and semaglutide for obesity — a head-to-head question that matters because the two are so often weighed against each other. Researchers reported greater 12-month total body weight loss with tirzepatide than semaglutide (16.6% vs 13.4%), with more tirzepatide users reaching ≥15% and ≥20% loss, and a larger gap among people without diabetes. Prior obesity-medication use was associated with less weight loss in both groups, and semaglutide users reported more gastrointestinal side effects (50.7% vs 28.5%). The design caveats are important: this is observational, not randomized, so channeling by clinician or patient preference, differing dose titration, and adherence can bias a head-to-head comparison; the cohort was predominantly White and female. Directionally consistent with randomized trial data favoring tirzepatide on weight, but read the magnitude cautiously given the observational design.
Mayo Clinic proceedingsn=—HumanJun 30, 2026 - Study · TirzepatideWeak / none
Endotypic trait responses to 12-month tirzepatide treatment for an obese patient with obstructive sleep apnea: a case report.
A single-patient case report from within the SURMOUNT-OSA trial: a 35-year-old man with severe obstructive sleep apnoea who, over 12 months of tirzepatide, saw his BMI fall from 31.0 to 24.9 and his apnoea-hypopnoea index drop from 54.8 to 4.4 events per hour, from severe to near-normal. The authors also report favourable shifts in underlying airway physiology (better upper-airway patency, stronger pharyngeal muscle response, lower loop gain), suggesting benefit beyond weight loss alone. The number to keep in view is n=1. A case report can illustrate a mechanism vividly but cannot establish how often, how much, or for whom such a result occurs; individual responses vary widely and single dramatic cases are selectively memorable. The larger SURMOUNT-OSA randomised trial is the appropriate evidence for tirzepatide and sleep apnoea; this vignette is a detailed physiological snapshot nested within that programme, useful for understanding how the effect might work, not for gauging its typical size. Read it as illustrative, not representative.
Obesity factsn=—HumanJun 30, 2026 - Study · TirzepatideMixed
Clinical benefits of tirzepatide in patients with steatotic liver disease and cardiometabolic dysfunction.
Using the TriNetX network, researchers propensity-matched 54,882 adults with steatotic liver disease and cardiometabolic dysfunction and reported that tirzepatide was associated with markedly lower rates of major adverse liver outcomes (HR 0.32), decompensation, hepatocellular carcinoma and liver transplantation, plus lower all-cause mortality (HR 0.22). The effect sizes are large, and that is precisely the reason for caution. In observational data, hazard ratios this extreme, especially a near-80% drop in all-cause mortality, often signal residual confounding: healthier or better-monitored patients may be the ones started on tirzepatide, and adherence differs from a trial. This is a retrospective association, not a causal or clinical finding; the authors explicitly call for prospective validation. Read it as a strong hypothesis worth testing in a randomized trial, not as established hepatic benefit. Framing matters here given how eye-catching the numbers are.
Communications medicinen=—HumanJun 29, 2026 - Study · TirzepatideWeak / none
A trispecific GLP-1/anti-GIPR/FGF21 peptibody exhibits favorable metabolic effects in a diet-induced obesity model.
A preclinical proof-of-concept in which tirzepatide is the benchmark, not the tested agent. Researchers engineered a trispecific ‘peptibody’ combining GLP-1 receptor agonism, GIP-receptor antagonism and FGF21-pathway activation, and characterised its binding and receptor activity in vitro before testing it in diet-induced-obesity mice. The construct (TA2) reduced body weight, improved glucose tolerance and lipids, and — notably — was associated with greater weight reduction than tirzepatide under generally comparable food intake, hinting at appetite-independent metabolic effects. Two things temper enthusiasm: this is a mouse model, and the GIPR-antagonism strategy sits in ongoing scientific debate, since tirzepatide itself is a GIPR agonist. Cross-agent comparisons in diet-induced-obesity mice do not predict human outcomes; tirzepatide's efficacy rests on large human Phase 3 trials this study does not touch. These are preclinical findings; human data are needed before clinical conclusions can be drawn.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapien=—AnimalJun 29, 2026 - Study · TirzepatideMixed
Neuropsychiatric association of tirzepatide and semaglutide in obesity with and without type 2 diabetes.
A large US electronic-health-record cohort study using a new-user, active-comparator design with 1:1 matching — a rigorous observational approach, but still observational. Over 24 months, both semaglutide and tirzepatide were associated with lower hazards of incident anxiety and depression versus naltrexone-bupropion, across patients with and without type 2 diabetes (hazard ratios roughly 0.5–0.8). Head-to-head, tirzepatide versus semaglutide was associated with modestly higher hazards of anxiety (HR 1.12) and insomnia (HR 1.13) in people without diabetes. These signals are reassuring against earlier concerns of psychiatric harm from these agents, and the effect sizes for depression are sizeable. The authors themselves flag residual confounding and diagnosis misclassification as key limits: people prescribed these drugs differ systematically from comparators, and record-based diagnoses are imperfect. Associations here cannot establish causation. Useful for monitoring and shared decision-making, not for concluding that either drug lowers mood-disorder risk.
Communications medicinen=—HumanJun 29, 2026 - Study · TirzepatideWeak / none
GLP-1 receptor agonists and Risk of Cardiovascular and Pulmonary Complications in patients with OSA and Type 2 Diabetes Mellitus.
A large retrospective database (TriNetX) cohort examining GLP-1 receptor agonists versus other diabetes medications for cardiovascular and pulmonary outcomes over 5 years in patients with obstructive sleep apnea (OSA) and type 2 diabetes. After propensity-score matching, researchers reported GLP-1RA use was associated with lower risk of acute respiratory failure versus several comparators (e.g., HR 0.78 vs DPP-4 inhibitors, 0.70 vs sulfonylureas) and lower risk of pulmonary hypertension, COPD, and heart failure versus some drug classes, plus fewer ED visits and admissions. The abstract frames this around tirzepatide (the first agent approved for moderate-to-severe OSA), but the exposure studied is the broader GLP-1RA class, not tirzepatide specifically. Caveats: observational design with confounding by indication, reliance on coded database records, and class-level rather than agent-level exposure. Weight it as a hypothesis-generating real-world signal; the authors themselves call for prospective studies.
Sleep & breathing = Schlaf & Atmungn=—HumanJun 27, 2026 - Study · TirzepatideMixed
GLP-1 receptor agonists in obstructive sleep apnea: A propensity score-matched real-world analysis.
A large retrospective, propensity-matched cohort study (roughly 439,000 patients per arm) using US network data, reporting that starting a GLP-1 receptor agonist around the time of an obstructive sleep apnoea diagnosis was associated with lower hazards of ischaemic stroke, intracranial haemorrhage, emergency visits, hospitalisations and all-cause mortality across one to five years. Associations held in CPAP-restricted and tirzepatide-specific subgroups. The scale is a strength; the design is the key caveat. This is observational data, showing association rather than causation, and is vulnerable to confounding by indication and healthy-adherer effects: people who start and stay on these drugs often differ systematically from those who do not. The authors themselves frame the results as hypothesis-generating, requiring prospective validation. Tirzepatide's own evidence is strongest in randomised trials for glycaemic control and weight loss; a dedicated sleep-apnoea outcomes trial, not a database analysis, is what would move this from signal to evidence.
Respiratory medicinen=—HumanJun 26, 2026 - Study · TirzepatideMixed
Tirzepatide Efficacy and Tolerability According to Early Weight Response: A Post Hoc Analysis of the SURMOUNT-1 and SURMOUNT-2 Trials.
This is a post hoc analysis of two pivotal Phase 3 tirzepatide trials (SURMOUNT-1 and -2; N=2384 in the tirzepatide arm), splitting participants by whether they lost at least 5% of body weight by Week 8. Both early and non-early responders reached clinically meaningful weight reduction and cardiometabolic improvement at Week 72, though early responders did better; gastrointestinal tolerability was similar between groups. The parent trials are registration-quality and double-blind, which anchors the data — but 'post hoc' matters: these subgroups were not randomised, the analysis is exploratory, and early responders differed at baseline (more likely female, White, lower HbA1c). The practical takeaway the authors draw is measured: a slow early response did not preclude meaningful longer-term benefit. Read this as a useful refinement of how to interpret early weight trajectories, not as a new efficacy claim beyond what SURMOUNT already established.
Diabetes, obesity & metabolismn=—HumanJun 25, 2026 - Study · TirzepatideMixed
Real-World Effectiveness of Semaglutide and Tirzepatide Compared With Bariatric Surgery.
A large retrospective real-world cohort (44,025 adults, BMI >=35, two urban health systems, 2018 to 2024) comparing weight loss on injectable semaglutide or tirzepatide against sleeve gastrectomy and gastric bypass, using inverse-probability weighting to balance groups. Researchers found bariatric surgery was associated with substantially greater total weight loss at 1 to 3 years: for example roughly 22 to 28% with surgery versus about 7 to 9% (semaglutide) and 11 to 12% (tirzepatide) in the per-protocol analysis. Tirzepatide outperformed semaglutide. Key caveats: this is observational, so residual confounding by indication remains despite weighting; medication adherence is imperfect (intention-to-treat numbers ran below per-protocol); and real-world dosing and persistence differ from trials. Weight it as a useful real-world magnitude comparison, not a randomized head-to-head. It reflects effectiveness as actually used, which for the drugs runs below the results seen in controlled trials.
Obesity (Silver Spring, Md.)n=—HumanJun 25, 2026 - Study · TirzepatideWeak / none
Cost-Effectiveness of Pharmacologic Therapies for Metabolic Dysfunction-Associated Steatohepatitis With Significant Fibrosis in the United States.
This is a health-economic modeling study, not a clinical trial; it asks whether drugs are cost-effective for MASH with F2 to F3 fibrosis at U.S. prices, using a Markov model fed by a Bayesian network meta-analysis. Researchers reported both semaglutide (ICER ~$80,076/QALY) and tirzepatide (~$42,705/QALY) fell below the $100,000/QALY threshold, while resmetirom did not. The output is only as good as its inputs: efficacy estimates came from an indirect network comparison, drugs were each compared to standard of care rather than head-to-head, and drug price was the dominant driver in sensitivity analysis. The authors explicitly caution that tirzepatide is not FDA-approved for MASH and its estimate rests on a Phase 2 trial via network meta-analysis. Weight this as a pricing/value argument for payers, not as evidence of clinical efficacy in MASH; neither peptide's fibrosis benefit is established here, only modeled.
Diabetes, obesity & metabolismn=——Jun 25, 2026 - Study · TirzepatideWeak / none
Tirzepatide, a dual GIP/GLP-1 receptor agonist, attenuates endothelial dysfunction and angiotensin II-induced abdominal aortic aneurysm in ApoE-/- mice.
This is a preclinical study combining cell-based assays with an angiotensin-II-infused ApoE-knockout mouse model of abdominal aortic aneurysm. Researchers reported that tirzepatide dampened TNFα-driven leukocyte–endothelium interactions, downregulated adhesion molecules (VCAM-1, ICAM-1) and chemokines, and suppressed NF-κB signalling; over 28 days of subcutaneous dosing it limited aortic expansion and reduced aneurysm incidence, with preserved elastin and less macrophage infiltration. Mechanistically this is a coherent story that extends tirzepatide's known anti-inflammatory and vascular signals beyond glycaemia and weight. But these are mechanistic findings in cells and mice; human data are needed before clinical conclusions can be drawn. Mouse aneurysm models do not map cleanly onto human aortic disease, the dosing and timeline are experimental, and no patient outcomes are involved. Weigh it as a plausible biological rationale worth testing — not as evidence tirzepatide affects aneurysm risk in people.
Pharmacological researchn=—AnimalJun 24, 2026 - Study · TirzepatideWeak / none
Tirzepatide Regulates Pacemaker Function by Modulating cAMP and Calcium Dynamics in Human Sinoatrial Node Cells.
No abstract was available for this item, so this note is based on the title alone and the study's findings cannot be assessed. The title indicates a laboratory (in-vitro) investigation of how tirzepatide influences pacemaker function in human sinoatrial-node cells, the heart's natural pacemaker, by acting on cAMP signalling and calcium handling. That points to mechanistic, cell-level cardiac research rather than a clinical outcomes study. Without the abstract, no result, effect size, direction, or caveat can be reported, and no conclusion about heart-rate effects in people should be drawn. In context, tirzepatide is well-studied in randomised trials for glycaemic control and weight loss, and GLP-1-based agents are known to modestly raise heart rate; a cell-based pacemaker study could speak to that mechanism, but the specifics here are unknown from the title. Published in Circulation, a high-profile cardiology journal, it is worth flagging for follow-up once the full text is available, but it supplies no usable findings as presented.
Circulationn=—In vitroJun 23, 2026 - Study · TirzepatideWeak / none
Experience with Tirzepatide and Weight Management During and After a Clinical Trial in Japanese Patients with Obesity Disease: A Qualitative Study.
This is a small qualitative exit-interview study (29 Japanese participants) exploring lived experience during and after the SURMOUNT-J tirzepatide trial — not an efficacy study. Its value is in texture, not effect sizes: most participants described appetite loss and changed eating habits on treatment, positive feelings about weight loss, and a wish to continue therapy; after the trial ended, many maintained eating changes but not exercise habits, and about two-thirds reported poorer appetite control. Qualitative work of this size cannot be generalised and is subject to recall and selection bias, and self-reported experience is not a clinical outcome. The findings echo a familiar pattern — weight-related benefits from incretin therapy tend to attenuate once treatment stops. Read it as a window into patient experience and unmet support needs, complementing rather than substituting for the quantitative SURMOUNT-J results.
Advances in therapyn=——Jun 23, 2026 - Study · TirzepatideWeak / none
Long-term effects of weight-reducing drugs in people with hypertension.
This is a Cochrane systematic review — the highest methodological tier — updating evidence on long-term weight-management drugs in people with essential hypertension (8 RCTs, ~13,000 participants). Its central finding is a gap: for the newest agents, semaglutide and tirzepatide, no results were reported for the review's critical outcomes (mortality, cardiovascular morbidity, serious adverse events) in hypertensive patients specifically. Older drugs showed mixed signals — orlistat probably increased serious adverse events; several agents increased overall adverse events — mostly at low or very low GRADE certainty. The honest conclusion is that evidence remains insufficient to judge whether pharmacological weight loss reduces death or cardiovascular events in people with hypertension. For tirzepatide this is a useful corrective: despite strong weight data, trial reporting has not isolated hypertensive subgroups for hard outcomes. Weigh it as a rigorous map of what we still don't know, and a call for disaggregated trial reporting.
The Cochrane database of systematic reviewsn=—HumanJun 19, 2026 - Study · TirzepatideMixed
Differential impact of pre-operative tirzepatide compared to glucagon-like-peptide-1 single receptor agonists on outcomes of spinal fusion surgery in obese patients.
This retrospective, propensity-matched cohort study (918 matched pairs from the TriNetX network) compares spinal-fusion outcomes in obese patients on tirzepatide versus single-receptor GLP-1 agonists. Researchers reported that the tirzepatide group had fewer early (90-day) thrombotic/embolic events (RR 0.41), urinary infections, and acute kidney injuries, and at two years fewer revisions (RR 0.65), pseudarthrosis (RR 0.41), and post-laminectomy syndrome. The direction and magnitude echo the companion lumbar-fusion cohort in this batch, which lends some internal consistency. Still, this is observational database research: propensity matching addresses measured confounders but not adherence, dosing, disease severity, or why a clinician chose one agent — and outcome coding can be imperfect. The authors frame it as 'potential protective physiological impact,' appropriately provisional. Weigh it as a converging hypothesis that tirzepatide's dual mechanism may aid surgical recovery, awaiting prospective, randomised confirmation before any clinical inference.
European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Societyn=—HumanJun 18, 2026 - Study · TirzepatideMixed
Cardiovascular outcomes of semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis.
This large systematic review and meta-analysis (47 RCTs, 59,352 participants) compares cardiovascular signals for semaglutide and tirzepatide. Researchers reported that semaglutide was associated with reduced major adverse cardiovascular events (RR 0.71), cardiovascular death, myocardial infarction, and heart failure, but not stroke. For tirzepatide, only a lower myocardial-infarction risk reached significance (RR 0.63), while the MACE reduction did not (RR 0.79, CI crossing 1). The crucial caveat, which the authors stress, is that most data came from separate drug-versus-control trials rather than head-to-head comparisons — so this cannot be read as evidence that one agent is cardiovascularly superior. The asymmetry more likely reflects tirzepatide's younger, thinner cardiovascular-outcomes evidence base (its dedicated CVOT is ongoing) than a true difference. Weigh semaglutide's signal as reasonably consistent and tirzepatide's as still limited and uncertain — an evidence-maturity gap, not a verdict.
Diabetology & metabolic syndromen=—HumanJun 18, 2026 - Study · TirzepatideMixed
Long-Term Mechanical Complications After Lumbar Fusion in Patients Receiving Tirzepatide vs Other GLP-1 Receptor Agonists.
This is a retrospective cohort study drawn from the TriNetX network, comparing lumbar-fusion outcomes in patients on tirzepatide versus other GLP-1 receptor agonists, with 1:1 propensity matching. Ninety-day safety and one-year mechanical outcomes were comparable, but by two and three years researchers reported significantly lower pseudarthrosis (3.1% vs 6.0% at three years, RR 0.51) and instrumentation failure (RR 0.43) in the tirzepatide group, with similar revision rates. The finding is intriguing but observational: propensity matching cannot eliminate confounding by indication, adherence, or unmeasured metabolic differences, and database studies can misclassify exposure and outcomes. This is an association that emerges only over extended follow-up, and the authors themselves call for prospective evaluation. Weigh it as a hypothesis-generating signal about tirzepatide's metabolic and anti-inflammatory effects on bone healing — not as evidence that one agent outperforms another for spinal fusion.
Spinen=—HumanJun 18, 2026 - Study · TirzepatideWeak / none
Psychiatric Safety Signals of GLP-1 Receptor Agonists: A FAERS-Based Pharmacovigilance Study with Explainable Machine Learning.
A disproportionality (pharmacovigilance) study of FDA adverse-event reports enhanced with machine learning, and its design dictates cautious reading. Spontaneous reporting databases like FAERS can flag potential signals but cannot establish causation, incidence, or risk, they are shaped by reporting biases, media attention, and prescribing volume. Across 211,195 cases, sixteen psychiatric preferred terms met signal criteria, with suicidal ideation most frequently reported (ROR 2.95), and signal magnitudes were consistently higher for semaglutide than tirzepatide. An explainable-ML model (AUROC 0.816) identified semaglutide use and younger age (19-44) as positively associated with psychiatric-event reporting, and age 65+ as negatively associated. These are associations within reporting patterns, not clinical risk estimates, and the authors themselves call for prospective study. Notably, regulators including EMA and FDA have previously reviewed GLP-1 suicidality signals without establishing a causal link. Weight this as hypothesis-generating surveillance that flags subgroups for scrutiny, not as evidence that semaglutide causes psychiatric harm.
Pharmaceuticals (Basel, Switzerland)n=——Jun 18, 2026 - Study · TirzepatideMixed
1-year outcomes of semaglutide, tirzepatide, and sleeve gastrectomy in obesity in type 2 diabetes: a retrospective cohort study.
This large real-world retrospective cohort (Epic Cosmos; 45,093 analysed) compares one-year outcomes of semaglutide, tirzepatide, and sleeve gastrectomy in adults with obesity and type 2 diabetes. The demanding composite endpoint — at least 20% weight loss plus HbA1c below 5.7% — was reached by an adjusted 3.0% on semaglutide, 13.2% on tirzepatide, and 24.0% after surgery, placing tirzepatide between the two. Emergency-department visits and new reflux/nausea prescriptions were more frequent after surgery. The scale is a strength, but the authors are candid about limitations: the groups differed at baseline (the surgical cohort was younger, heavier, with lower HbA1c), and residual confounding plus a narrow safety scope constrain interpretation. This is not a randomised comparison, and one-year data cannot speak to durability. Consistent with tirzepatide outperforming semaglutide on weight while surgery remains most potent, weigh it as informative real-world benchmarking — hypothesis-refining, not a definitive ranking.
The lancet. Diabetes & endocrinologyn=—HumanJun 17, 2026 - Study · TirzepatideWeak / none
Adjunctive GLP1 Receptor Agonists in Patients with Inflammatory Bowel Diseases and Obesity and/or Diabetes: A Target Trial Emulation.
This is a target-trial-emulation cohort study using administrative claims to test whether adding semaglutide or tirzepatide changes outcomes in patients with stable inflammatory bowel disease plus obesity and/or diabetes. Across two cohorts (2,028 and 346 matched pairs), researchers found no significant difference in one-year IBD relapse or safety outcomes between GLP-1RA initiators and non-initiators; notably, roughly a third of patients discontinued the drug within a year. Target-trial emulation is a rigorous approach to observational data, strengthening causal interpretation, but it remains non-randomised — residual confounding, claims-based outcome definitions, and high discontinuation all temper conclusions. The finding is essentially null, and null results are informative here: they push back on the idea that incretin therapy meaningfully modifies IBD activity in already-stable patients. Weigh it as reassuring evidence of no clear relapse signal in either direction, not as evidence of an IBD-specific benefit.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Associationn=—HumanJun 17, 2026 - Study · TirzepatideSupported
Pharmacologic Treatments With Lifestyle Modifications in Nonpregnant Adults With Overweight or Obesity in Outpatient Settings: A Living Clinical Guideline From the American College of Physicians (April 2026).
This is a clinical guideline from the American College of Physicians (April 2026), built on the accompanying systematic reviews, rather than a primary study. Guidelines synthesise evidence into practice guidance, and this one uses GRADE and issues only conditional recommendations, signalling genuine uncertainty and a strong role for patient preference. For adults with obesity (BMI 30 or higher), ACP positions semaglutide and tirzepatide as first-line options, both on moderate-certainty evidence, with phentermine-topiramate, liraglutide and naltrexone-bupropion as later lines on low-certainty evidence. The guidance is careful about harms and access: it foregrounds contraindications and warnings (cardiovascular contraindication and monthly pregnancy testing for phentermine-topiramate, suicidal ideation with naltrexone-bupropion) and directs clinicians and patients to weigh benefits, harms, cost, availability, comorbidities and values together. For readers, the takeaway is that the two peptide agents here now sit at the top of a mainstream professional-society algorithm, but as conditional suggestions paired with shared decision-making, not directives.
Annals of internal medicinen=——Jun 16, 2026 - Study · RetatrutideSupported
Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.
A living systematic review and network meta-analysis for the American College of Physicians, and one of the strongest evidence syntheses in this batch: 69 randomised controlled trials, 112,511 participants, with 37 trials at low risk of bias. Network meta-analysis lets researchers rank treatments partly through indirect comparison, useful when head-to-head trials are scarce, but indirect estimates carry more uncertainty than direct ones. Researchers reported that nearly all drugs beat placebo or lifestyle intervention for weight loss while causing more adverse-event discontinuations; that semaglutide probably reduced mortality and major cardiovascular events; and that semaglutide and tirzepatide produced the greatest weight loss in both pairwise and network analyses. Crucially, the authors flagged that evidence for mortality, cardiovascular events and serious adverse events was limited and direct head-to-head data sparse, so the weight-loss ranking is far more certain than the hard-outcome claims. Weight this as high-quality comparative evidence for weight change, and more cautiously for survival and cardiovascular benefit.
Annals of internal medicinen=—HumanJun 16, 2026 - Study · TirzepatideWeak / none
Cost-Effectiveness of Pharmacologic Treatments in Adults With Overweight or Obesity: A Systematic Review for the American College of Physicians.
A systematic review of cost-effectiveness, not clinical efficacy, prepared for the American College of Physicians. It asks whether weight-management drugs deliver value for money in a US setting, using incremental cost-effectiveness ratios and GRADE certainty. The headline finding is about the weakness of the evidence: across nine included studies and 42 pairwise comparisons, none reached high certainty, and all were model-based rather than trial-based. Within six moderate-certainty studies, researchers reported that tirzepatide (and phentermine-topiramate) showed high value versus lifestyle modification, while liraglutide showed low value; semaglutide showed low value against naltrexone-bupropion and phentermine-topiramate but high value against liraglutide. These are economic-model outputs, highly sensitive to drug-price assumptions, willingness-to-pay thresholds and modelled horizons, so conclusions shift as prices move. The reviewers were explicit that poor study quality limits firm conclusions. Read this as a map of where the economic evidence is thin, not as a durable value ranking, and separate cost-effectiveness entirely from questions of clinical benefit or safety.
Annals of internal medicinen=——Jun 16, 2026 - Study · TirzepatideMixed
Tirzepatide for Obesity in Adults ≥ 65 Years: A Post Hoc Analysis of the SURMOUNT and SUMMIT Clinical Trials.
A post hoc analysis pooling Eli Lilly's Phase 3 obesity programme (SURMOUNT-1 through -5, SURMOUNT-OSA and SUMMIT) to ask whether tirzepatide behaves differently in adults aged 65 and over. That question matters because older patients are underrepresented in registration trials, yet post hoc subgroup splits are exploratory: age was not a pre-specified randomisation factor, so this is hypothesis-consistent rather than confirmatory evidence. Researchers reported that weight reduction, cardiometabolic risk factors and quality-of-life measures in the older group broadly matched those in adults under 65, and that adverse-event rates versus placebo showed no clinically meaningful age-related excess for gastrointestinal tolerability, falls, fractures, depression, pancreatitis, or renal, hepatic, gallbladder and biliary events. Read against tirzepatide's large, high-quality Phase 3 base, this extends confidence to older adults but does not replace a trial designed to test them. Note too that trial participants are typically healthier than the general geriatric population, and the abstract does not detail muscle- or bone-loss outcomes that weight loss can raise in this age group.
Diabetes, obesity & metabolismn=—HumanJun 16, 2026 - Study · TirzepatideSupported
Comparative Effects of Antidiabetic Drugs on Body Composition: A Systematic Review and Network Meta-Analysis.
This systematic review and network meta-analysis (41 RCTs, 2,906 participants) compares antidiabetic drugs' effects on body composition — fat mass and lean body mass. Among incretin therapies, tirzepatide showed the greatest fat-mass reduction versus placebo (MD −10.70 kg), ahead of semaglutide and liraglutide; but it was also associated with the largest lean-mass reduction (MD −4.40 kg). That dual finding is the substantive contribution: the potent fat loss from GIP/GLP-1 agonism comes with meaningful lean-mass loss, and the review notes exercise mitigated liraglutide-related lean-mass loss. Network meta-analyses allow indirect comparisons across trials but rest on assumptions of transitivity and consistency, and the total sample is modest with likely heterogeneity in how body composition was measured. Consistent with growing attention to muscle preservation during rapid weight loss, weigh this as useful comparative evidence on composition — while remembering that lean-mass change is not equivalent to functional or clinical outcomes, which the analysis does not assess.
Diabetes, obesity & metabolismn=—HumanJun 16, 2026 - Study · TirzepatideWeak / none
Tirzepatide for Excess Weight in Adults With Type 1 Diabetes Using MiniMed 780G.
This entry has no abstract available, so this note is title-based. The title indicates a study of tirzepatide for excess weight in adults with type 1 diabetes using the MiniMed 780G automated insulin-delivery system — a population outside tirzepatide's approved indications (type 2 diabetes and obesity) and largely outside its Phase 3 evidence base (SURPASS, SURMOUNT), which did not focus on type 1 diabetes. Without the abstract, the design, sample size, glycaemic and weight results, and any adverse events are unknown, so no findings can be reported here. Off-label use of an incretin therapy in type 1 diabetes raises specific safety considerations — including hypoglycaemia interactions with insulin automation and, theoretically, ketoacidosis risk — that this record does not let us assess. Weigh it only as a signal that this question is being studied; the primary source is needed before any conclusion.
Diabetes, obesity & metabolismn=——Jun 16, 2026 - Study · TirzepatideSupported
Tirzepatide monotherapy in Chinese patients with early type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO).
A registration-quality randomised, double-blind, placebo-controlled Phase 3 trial (SURPASS-CN-MONO) testing tirzepatide monotherapy in 206 Chinese adults with early, treatment-naive type 2 diabetes across 29 centres, funded by Eli Lilly. The blinded, placebo-controlled design and pre-specified HbA1c primary endpoint place this near the top of the evidence hierarchy; its main limits are modest size and 40-week duration, which do not speak to long-term or cardiovascular outcomes. Researchers reported HbA1c reductions of 2.04% to 2.17% across the 5, 10 and 15 mg doses versus a 0.13% placebo change (all p<0.001), and weight reductions of 6.0 to 9.7 kg versus 1.0 kg, with gastrointestinal events the most common treatment-emergent effect and no clinically significant or severe hypoglycaemia. These results are consistent with the broader SURPASS programme and add region-specific data for an East Asian population. Weight it as solid confirmatory evidence within diabetes; the industry funding and short horizon are the caveats to keep in view.
Med (New York, N.Y.)n=—HumanJun 15, 2026 - Study · TirzepatideWeak / none
SURMOUNT-REAL UK: A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With Obesity.
This is a study-design paper describing SURMOUNT-REAL UK, a planned 5-year, Phase 4, open-label pragmatic randomised trial, not a results report. It is worth logging precisely because of what it will test: effectiveness of tirzepatide added to standard care in UK primary care for around 3,000 adults with Class I obesity (BMI 30-34.9) and no diabetes, using linked electronic health records, with percent weight change at 24 months as the primary endpoint and time to onset of type 2 diabetes at 60 months as a key secondary. Pragmatic, open-label trials trade the internal rigour of blinded efficacy trials for external validity, real-world effectiveness under ordinary conditions, which complements the tightly controlled SURMOUNT efficacy programme. No outcomes exist yet; open-label design and reliance on routine records introduce measurement and behaviour caveats that only the eventual data will resolve. For readers, the signal here is that a real-world effectiveness and diabetes-onset question is being asked at population scale, not that any finding has landed.
Obesity (Silver Spring, Md.)n=—HumanJun 15, 2026 - Study · TirzepatideWeak / none
Temporal Trends and Clinical Characteristics of Incretin-Based Therapy Use in Women With Polycystic Ovary Syndrome: A Real-World Cohort Study From a Polish Private Healthcare Network.
A large real-world cohort (38,263 women with coded PCOS in a Polish private network) describing how fast GLP-1 and GIP/GLP-1 receptor-agonist prescribing has grown in this population. This is a descriptive electronic-health-record study of prescribing patterns, not an efficacy or outcomes trial: it tells us who is being prescribed these drugs and how the trend is moving, not whether they help PCOS-specific endpoints. Researchers reported that recorded initiation within a year of PCOS diagnosis rose from 0.14% in 2018 to 5.97% in 2024, that users had higher BMI and greater comorbidity burden than metformin-only or untreated women, and that only 11.5% carried a type 2 diabetes code, suggesting weight- and cardiometabolic-driven use rather than glycaemic indication. The value here is a market and practice signal. Its limits are real: EHR prescribing records do not confirm dispensing, adherence, or clinical response, and a single private network in one country may not generalise. The authors themselves call for dispensing, persistence, safety and outcome studies.
Diabetes, obesity & metabolismn=—HumanJun 15, 2026 - Study · TirzepatideMixed
Effectiveness of tirzepatide in Japanese patients with type 2 diabetes but no obesity: A sub-analysis of Hokkaido-TZP study data.
A secondary analysis of the real-world, multicentre Hokkaido-TZP study focused on 107 Japanese adults with type 2 diabetes but without obesity (BMI under 25), a group excluded from the Phase 3 SURPASS trials, which required BMI of at least 23. That makes the question genuinely useful, since lean type 2 diabetes is common in Asia and under-evidenced. But the design is observational and small: no control group, 6-month follow-up, and a subgroup carved from a larger cohort, so glycaemic changes cannot be attributed to the drug with trial-level confidence. Researchers reported that over six months tirzepatide was associated with significant HbA1c reductions across all baseline-BMI tertiles, and with a significant overall BMI decrease that was larger in those with higher starting BMI; baseline BMI and dietary consultation independently predicted the degree of BMI reduction. Seven patients discontinued for adverse events, all in the lower- and middle-BMI groups, a tolerability signal worth noting in leaner patients. Weight this as supportive real-world data extending tirzepatide's glycaemic use to non-obese patients, pending controlled confirmation.
Journal of diabetes investigationn=—HumanJun 14, 2026 - Study · TirzepatideMixed
Sex, Not Age, Predicts Weight Loss Outcomes With Tirzepatide: A Retrospective Analysis.
A single-centre retrospective cohort (1,039 Mayo Clinic patients on tirzepatide for at least 12 months) asking which patient factors predict weight loss in ordinary practice. Retrospective real-world cohorts capture everyday effectiveness that trials miss, but they carry selection and confounding limits: this sample is restricted to people who stayed on therapy 12 months or more, filtering out early discontinuers and so likely flattering the average response. Within that frame, researchers reported that women lost more total body weight than men at 15 months (15.1% versus 10.7%), and that in multivariable analysis greater loss tracked with female sex, absence of type 2 diabetes, no prior obesity medication, no weight-gain-promoting co-medications, and higher tirzepatide dose, while age was not an independent predictor. The headline, sex not age, is a useful counter to an intuitive assumption, but a single-centre design and the persistence filter limit generalisability, and residual confounding (for example dose titration reflecting tolerability) is hard to exclude. Treat this as a hypothesis-refining observation for personalising expectations, not a causal rule.
Obesity (Silver Spring, Md.)n=—HumanJun 14, 2026 - Study · TirzepatideMixed
The Efficacy of Glucagon-like Peptide-1 Based Therapies in Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction: A Systematic Review and Meta-Analysis.
This systematic review and meta-analysis (14 RCTs, 15,180 participants, rated low risk of bias, PROSPERO-registered) pools GLP-1-based therapies — including tirzepatide — across the heart-failure spectrum. Researchers reported a modest reduction in heart-failure hospitalisation overall (RR 0.84, 95% CI 0.71–0.99), with a larger signal in HFpEF patients with stable coronary disease (RR 0.61) and in the composite of hospitalisation plus cardiovascular death for HFpEF (RR 0.67). A meta-analysis sits high on the evidence hierarchy, but it inherits the limits of its inputs: the subgroup effects rest on fewer trials with wider intervals, and the exenatide-in-HFmrEF finding is explicitly flagged as limited. This aligns with tirzepatide's registration-grade base and the emerging cardiovascular picture, but the authors frame effects as phenotype-specific rather than universal. Weigh it as supportive, hypothesis-refining evidence.
Journal of clinical medicinen=—HumanJun 9, 2026 - Study · SemaglutideWeak / none
Do GLP-1 Receptor Agonists Sabotage Fat Grafts? A Scoping Review of GLP-1 Receptor Agonist Effects on Adipocyte Biology and Implications for Autologous Fat Transfer.
This scoping review maps mechanistic reasons GLP-1-class drugs might interfere with autologous fat grafting, but the authors stress no clinical or preclinical studies have directly examined this outcome. The conclusions are explicitly hypothesis-generating rather than evidence-based. Retatrutide is mentioned partly in the context of off-label bodybuilding use.
Aesthetic surgery journaln=——Jun 1, 2026 - Study · TirzepatideWeak / none
Longitudinal 18F-Fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET) Findings in Korsakoff Syndrome After Rapid Weight Loss During Tirzepatide Therapy: A Case Report.
This single case report describes a 50-year-old man with obesity and chronic alcohol use disorder who developed Korsakoff syndrome during rapid weight loss temporally associated with tirzepatide, a dual GLP-1/GIP receptor agonist. Brain imaging showed hypometabolism in the mammillary bodies progressing to the thalamus and brainstem, and cognitive deficits persisted despite intravenous thiamine. A case report establishes temporal association only, not causation; the patient's alcohol use is itself a major risk factor for thiamine-deficiency brain injury, and rapid caloric restriction from any cause could contribute. The value here is a clinical caution: the authors flag that reduced nutritional intake during incretin-based weight loss may unmask thiamine deficiency in vulnerable people. For tirzepatide readers this is a safety signal warranting nutritional vigilance, not evidence of a common or drug-specific harm.
Cureusn=—HumanJun 1, 2026 - Study · TirzepatideMixed
Clinical Implications of Mounjaro (Tirzepatide) for Breast Cancer Detection and Management: A Narrative Review.
This narrative review examines how tirzepatide (Mounjaro) intersects with breast cancer detection and management — a practical question as more women in breast clinics are using it. The authors summarize a reassuring evidence picture: randomized-trial data and meta-analyses to date show no clear evidence of increased breast cancer incidence with tirzepatide or GLP-1 agents, and clinical use in women with breast cancer has been associated with meaningful weight loss without short-term safety signals. They also note preclinical models where tirzepatide-associated weight loss reduced mammary tumor progression, while flagging that the clinical relevance is uncertain. The imaging angle is the useful nuance: rapid weight loss can make benign lumps more palpable and shift mammographic density, but available data do not indicate reduced imaging accuracy. As a narrative review it grades no evidence and pools no data; its value is orienting clinicians and patients, with the authors calling for prospective imaging and oncology studies.
Cureusn=——Jun 1, 2026 - Study · TirzepatideMixed
Weight-loss dynamics with tirzepatide versus semaglutide.
This large real-world retrospective cohort (10,339 matched pairs from electronic health records) compares weight-loss dynamics for tirzepatide versus semaglutide, using AI-assisted note curation for adverse events. Researchers reported greater mean weight reduction with tirzepatide (14.7% vs 10.8%), nearly double the rate of high responders (≥15% in year 1: 42.6% vs 21.6%), faster weight-loss velocity, and a lower recorded prevalence of gastrointestinal and systemic adverse events. Because both cohorts drew on routine care with 1:1 propensity matching, the comparison is more directly head-to-head than pooled trial data — a genuine strength. But confounding by indication, dosing differences, adherence, and AI-based adverse-event extraction from free text are real limitations, and demographic disparities in response (by sex and race) warrant caution about generalising. This aligns with the pattern seen in randomised comparisons like SURMOUNT-5. Weigh it as strong, direction-consistent real-world evidence that tirzepatide is associated with greater weight loss, while treating the safety comparison as exploratory.
PNAS nexusn=—HumanJun 1, 2026 - Study · TirzepatideWeak / none
Anterior Cutaneous Nerve Entrapment Syndrome From Glucagon-Like Peptide-1 Receptor Agonist Injection.
This is a single case report — the weakest design for causal inference, but valuable for pharmacovigilance. Clinicians describe a 44-year-old man who developed focal, nerve-type abdominal pain (anterior cutaneous nerve entrapment syndrome, ACNES) coinciding with starting tirzepatide injections; the pain improved after moving injections away from the abdomen and adding pain medication. The authors present it as the first documented ACNES case linked to a GLP-1-type injection. A case report cannot establish incidence, causation, or whether tirzepatide itself (versus the injection technique or site) is responsible — the temporal association and response to injection-site change are suggestive, not confirmatory. Its practical worth is a reminder to consider ACNES when focal abdominal pain appears with subcutaneous incretin therapy, and that relocating the injection site is a simple first step. Weigh it as a clinical signal and teaching case, not evidence of a common risk.
ACG case reports journaln=—HumanJun 1, 2026 - Study · TirzepatideMixed
Glucagon-Like Peptide-1 Receptor Agonists Improve Cardiovascular Outcomes in Heart Failure with Preserved Ejection Fraction, Independent of Diabetes: A Systematic Review and Meta-Analysis.
This systematic review and meta-analysis (11 studies) asks whether GLP-1RA and tirzepatide benefits in HFpEF/HFmrEF depend on diabetes status. In pooled RCT data, researchers reported reductions in heart-failure hospitalisation/events (HR 0.68) and in the composite of cardiovascular death or HF events (HR 0.76), with observational data pointing the same way (HR 0.60); meta-regression found no evidence that type 2 diabetes modified the effect. That 'independent of diabetes' signal is the notable contribution, reinforcing that cardiovascular benefit may extend beyond glucose lowering. Caveats matter: only 11 studies, a mix of RCTs, post-hoc analyses and observational data, and an exploratory network meta-analysis that found no significant difference between agents — so it cannot rank one drug over another. Consistent with tirzepatide's SUMMIT signal and semaglutide's STEP-HFpEF data, this is supportive, well-aligned evidence, best read as strengthening a converging picture rather than settling it.
CJC openn=—HumanJun 1, 2026 - Study · TirzepatideWeak / none
Tirzepatide: A turning point in obesity related heart failure with preserved ejection fraction?
This is a short commentary framed as a question — no abstract was available, so this note is title-based and read against the wider evidence for tirzepatide. Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist whose Phase 3 record (SURPASS, SURMOUNT) sits in glycaemic control and weight reduction; its heart-failure signal rests chiefly on the SUMMIT trial in obesity-related HFpEF. A piece asking whether the drug is a 'turning point' should be read as expert framing, not new data — it reports no primary outcomes, effect sizes, or confidence intervals of its own. Weigh it as context rather than evidence. Readers who want the underlying result should go to the trial it discusses; as with any single opinion piece, the headline claim is the author's interpretation.
JPMA. The Journal of the Pakistan Medical Associationn=——Jun 1, 2026 - Study · TirzepatideWeak / none
Glucagon-like peptide-1 receptor agonists as a metabolic optimization strategy in surgical prehabilitation: a translational perspective.
A narrative "translational perspective" proposing, but not testing, the idea of using GLP-1 receptor agonists (semaglutide, tirzepatide) as a metabolic-optimization adjunct in prehabilitation before major surgery. The authors are refreshingly candid that there is currently no direct evidence supporting this use; the piece argues biological plausibility (metabolic optimization, sarcopenic obesity, oncologic and bariatric context) while flagging a concrete perioperative safety concern, delayed gastric emptying and aspiration risk, and pointing to current anesthetic guidance. Weight this as hypothesis-generating commentary, not evidence: it maps a research agenda rather than reporting outcomes. The value is in framing the open questions and the safety trade-offs; any clinical use in this setting would require prospective trials of feasibility, safety and meaningful outcomes, which do not yet exist.
Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgeryn=——Jun 1, 2026